 ,,,,,,,,Phys-Chem,,,,,,,Caco2 Ellinger,Vero-E6 Zaliani ,Vero-E6 Touret,HRCE Heiser,3CLPro Kuzikov,,Vero-E6 Riva,Bakowski,SARS-CoV Pseudotyped particle entry Vero E6 - NCATS and PubChem (AID:1479145),,,,,SARS-CoV Pseudotyped particle entry Vero E6 (Tox counterscreen)- NCATS and PubChem (AID:1479150),,,,,,MERS Pseudotyped particle entry Huh7 - NCATS and PubChem (AID:1479149),,,,,MERS Pseudotyped particle entry Huh7 (Tox counterscreen) - NCATS and PubChem (AID:1479147),,,,,,"SARS-CoV-2 cytopathic effect (CPE) - NCATS, PubChem (AID:1508606) and Chen",,,,,,,"SARS-CoV-2 cytopathic effect (CPE)(Tox counterscreen) - NCATS, PubChem (AID:1508605) and Chen",,,,,,,,,,,Red Flags,,,
Name,Indication (1),Pathway (1),Target (1),MOA(1),EC50 value,IC50 value,pIC50 value,MW,logP,HBA,HBD,RotBonds,PSA,NoChiralCentres,% inhibition,% inhibition,Inhibition index,Hit score,% inihibition,IC50 (nM),%Viral inhibition,Calu3 EC50 GeoMean (µM),AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,Tox,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,Tox,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,CPE EC50 (uM),CPE % Efficacy,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,Tox,Cytotox CC50 (uM),% Cytotox,protein-binding,t_half (Half-life),BA (Bioavailability),Drug interactions,Contraindications,Pregnancy concerns,Breast feeding
Tolterodine (tartrate),"Urinary antispasmodics, Overactive bladder agent","Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",acetylcholine receptor antagonist,,,8.2006,475.582,3.21882,6,5,10,138.53,3,,,1.165,,,,,,39.81071706,-10.0597169,,,,0,-139.3818361,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,96.30%,1.9-3.7h,,None,Urinary/gastric retention; uncontrolled narrow angle glaucome;,Category B3,Not recommended
Palonosetron (Hydrochloride),Anti-emetic,Serotonergic synapse,HTR3A,serotonin receptor antagonist,,,,332.875,3.0783,2,0,1,23.55,4,57.4,0.02,0.9614,0.1883,-0.9864,,,,0,-37.19548142,0,0,Inactive,0,0.901762345,0,0,Inactive,Inactive,28.18382931,-83.07818418,28.1838,42.755,Inconclusive,0,-12.23620792,0,0,Inactive,Inactive,0,-1.975933887,,,,,,0,-30.35097602,,,,,,,62%,~40h,,Apomorphine,"Hypersensitivity; When co-administered with apomorphine, causes hypotension and loss of consciousness",Category B1,Use with caution
Dapoxetine (hydrochloride),Antidepressant,Serotonergic synapse,"HTR1A, HTR1B, HTR2C, SLC6A4",selective serotonin reuptake inhibitor (SSRI),,,,341.882,5.3334,2,0,6,12.47,1,65.1,0.09,,,5.583,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1-2h,,NA,NA,Category C,Not recommended
Solifenacin (Succinate),Attention Deficit Hyperactivity Disorder Agent,Synaptic vesicle cycle,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",acetylcholine receptor antagonist,,,7.197,480.561,3.8007,5,2,5,107.38,4,15.21,0.15,,,22.54,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,93-96%,33-85h,,Itraconazole; Lefamulin,Hypersensitivity; gastric retension; narrow-angle glaucoma,Category B3,Not recommended
Indinavir (sulfate),Anti-HIV,Protein biosynthesis,"CYP3A4, CYP3A5, CYP3A7",HIV protease inhibitor,,150,6.824,711.882,2.2141,9,6,11,192.63,5,,,0.3816,,,,,,0,-99.34935433,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,6.044445246,0,0,Inactive,0,0.660333522,0,0,Inactive,Inactive,0,16.6195617,,,,,,0,-22.93077735,,,,,,,60%,1.8h,,Alfuzosin; amiodarone; cobicistat; cobimetinib; conivaptan; dihydroergotamine; dihydroergotamine intranasal; eliglustat; elvitegravir/cobicistat/emtricitabine/tenofovir DF; ergoloid mesylates; ergonovine; etravirine; finerenone; flibanserin; irinotecan; irinotecan liposomal; isavuconazonium sulfate; ivabradine; lomitapide; lonafarnib; lovastatin; lurasidone; methylergonovine; naloxegol; regorafenib; salmeterol; simvastatin; St John's Wort; tipranavir; venetoclax; voclosporin,Hypersensitivity,Category B3,Not recommended
Tiagabine (hydrochloride),Anticonvulsants,GABAergic synapse,SLC6A1,GABA uptake inhibitor,,,6.829,412.02,5.46664,4,1,6,40.54,1,31.5,0.01,0.2483,,-8.564,,,,3.981071706,-23.56476591,3.9811,37.5546,Inconclusive,0,-6.606118034,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,10.91633539,0,0,Inactive,Inactive,0,-2.59636294,,,,,,0,-33.52579994,,,,,,,96%,7-9 hours,,None,Hypersensitivity,Category B3,Use with caution
Ethambutol (dihydrochloride),Antibacterial (tuberculostatic),NA,,bacterial cell wall synthesis inhibitor,,,6.209,277.236,0.551,4,4,9,64.52,2,8.87,0.05,,,21.74,,,,0,-86.39508515,0,0,Inactive,0,4.141143292,0,0,Inactive,Inactive,0,5.762307416,0,0,Inactive,0,1.05984262,0,0,Inactive,Inactive,0,-2.452928521,,,,,,0,-16.78227429,,,,,,,Ethambutol is 20-30% bound to protein in plasma. Data regarding which proteins ethambutol binds to are not readily available,"Ethambutol has a half life of 3.3 hours in patients with normal renal function. In patients with renal failure, the half life could be 7 hours or longer",75-80%,None,Hypersensitivity; Optic neuritis; changes in vision,Category A,Recommended
Telotristat etiprate,Antidiarrheal,"Tryptophan metabolism, Seratonergic synapse",TPH1,tryptophan hydroxylase inhibitor,,,7.796,754.166,5.48962,11,4,12,197.57,2,3.02,0.17,,,8.235,,,,39.81071706,-68.04863548,0,0,Inactive,0,-19.81621671,0,0,Inactive,Inactive,0,4.186659697,0,0,Inactive,0,1.158913405,0,0,Inactive,Inactive,0,13.9536923,,,,,,0,-10.74923334,,,,,,,"High plasma protein binding of its active metabolite, Telotristat.",4–12 h,,NA,NA,Category B3,Not recommended
Pergolide (mesylate),Antiparkinsonian,"Neuroactive ligand-receptor interaction, Dopaminergic synapse","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",dopamine receptor agonist,,,,410.605,3.7751,4,2,4,73.4,3,1.63,-0.14,1.047,,0.07731,,,,0,-36.7887671,0,0,Inactive,0,0.203604935,0,0,Inactive,Inactive,39.81071706,-17.85025251,39.8107,49.898,Inconclusive,0,0,0,0,Inactive,Inactive,0,1.585786295,,,,,,0,-18.38445142,,,,,,,90%,27 h,,NA,NA,Category C,NA
Pyrantel (tartrate),Anthelmintic,NA,,"acetylcholine receptor agonist, nicotinic receptor agonist",,,,356.4,0.3727,7,4,5,130.66,2,,,0.1796,,,,,,0,-9.907019226,0,0,Inactive,0,-15.82883637,0,0,Inactive,Inactive,0,-92.44778293,0,0,Inactive,0,-3.029288205,0,0,Inactive,Inactive,0,3.597812835,,,,,,0,-17.98430674,,,,,,,,1.75 h,,None,Hypersensitivity; Intestinal obstruction; Hepatic disease,Category B2,Not much information is available
Delavirdine (mesylate),Anti-HIV,RNA replication/synthesis,CYP3A4; HIV1,non-nucleoside reverse transcriptase inhibitor,,,7.4437,552.679,2.2211,8,4,6,164.8,0,-1.61,0.21,,,83.7,3990,,,,,,,,,,,,,,,,,,,,,,,,,0,-8.024277089,,,,,,0,-13.59541524,,,,,,,98%,5.8 h,,Esomeprazole; Ritonavir; Mirtazapine,NA,Category B3,NA
Eletriptan (hydrobromide),"Antimigraine, Vasoconstrictor,","Neuroactive ligand-receptor interaction, Seratonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7",serotonin receptor agonist,,,,463.441,4.3989,3,1,6,53.17,1,0.96,0.08,,,3.937,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,85%,4 h,0.5,Almotriptan; bromocriptine; cabergoline; chloramphenicol; cobicistat; dihydroergotamine; dihydroergotamine intranasal; ergoloid mesylates; ergotamine; frovatriptan; lopinavir; methylergonovine; mifepristone; naratriptan; rizatriptan; saquinavir; sumatriptan; sumatriptan intranasal; tipranavir; zolmitriptan,Hypersensitivity; Ischemic coronary artery disease,Category B1,Use with caution
Cefuroxime (sodium),Antibacterial,Peptidoglycan biosynthesis,,bacterial cell wall synthesis inhibitor,,2.09E+03,,446.373,-4.8667,10,2,7,176.59,2,-2.78,0.11,0.2609,,-3.438,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50%,80mins,0.52,None,Hypersensitivity,Category B1,Use with caution
Darifenacin (hydrobromide),Urinary antispasmodics,"Neuroactive ligand-receptor interaction, Cholinergic synapse","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",acetylcholine receptor antagonist,,,,507.472,4.5354,3,1,7,55.56,1,-5.74,0.01,0.6317,,14.06,,,,0,-7.468185967,0,0,Inactive,0,-4.063350921,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.960180621,0,0,Inactive,Inactive,0,-0.606797644,,,,,,0,-31.74358728,,,,,,,98%,13-19 h,15-19%,Eliglustat,Urinary retention; Uncontrolled narrow-angle glaucoma; Severe hepatic impairment; Paralytic ileus; GI or Gu obstruction; Hypersensitivity,Category B3,Use with caution
Alogliptin (Benzoate),Antidiabetic,Protein digestion and absorption,DPP4,dipeptidyl peptidase inhibitor,,,8,461.522,1.77928,8,2,4,134.35,1,-0.02,0.07,,,16.4,,,,0,2.234603,0,0,Inactive,0,-12.51693882,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,,,,,,,,,,,,,,,,20%,21 h,1,None,Hypersensitivity; Stevens-johnson syndrome,Category B3,Use with caution
(S)-Rasagiline,Antiparkinsonian,"Seratonergic synapse, Dopaminergic synapse","BCL2, MAOB",monoamine oxidase inhibitor,,,8.3979,171.243,1.8967,1,1,2,12.03,1,,0,,,19.35,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,88-94%,3 h,0.36,Apraclonidine; atomoxetine; brimonidine; bupropion; cyproheptadine; desvenlafaxine; deutetrabenazine; dexmethylphenidate; dextroamphetamine; dextromethorphan; ephedrine; fentanyl; fentanyl intranasal; fentanyl transdermal; fentanyl transmucosal; isocarboxazid; levomilnacipran; lisdexamfetamine; meperidine; methadone; methamphetamine; methylphenidate; milnacipran; mirtazapine; ozanimod; phenelzine; phenylephrine PO; procarbazine; pseudoephedrine; safinamide; selegiline; solriamfetol; St John's Wort; tapentadol; tetrabenazine; tramadol; tranylcypromine; vilazodone; vortioxetine,NA,Category B3,Use with caution
Erlotinib (Hydrochloride),Antineoplastic,"MAPK signaling pathway, ErbB signaling pathway","EGFR, NR1I2",EGFR inhibitor,,,10.5228,429.904,3.8269,7,1,10,74.73,0,25.79,-0.22,,,-0.1805,,,,15.84893192,-59.67210683,,,,0,0,,,,,,,,,,,,,,,,0,-11.22576462,,,,,,8.912509381,-99.7611631,,,,,,,93%,36.2 h,60%; With food 100%,Dexlansoprazole; esomeprazole; lansoprazole; omeprazole; pantoprazole; rabeprazole,None,Category C,Not recommended
Anagrelide (hydrochloride),"Thrombocythemia treatment, Platelet aggregation inhibitor",Purine metabolism,PDE3A,phosphodiesterase inhibitor,,,7.086,292.553,2.3481,3,1,0,44.7,0,3.09,-0.03,,,5.284,,,,0,-35.48479791,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.580106196,0,0,Inactive,Inactive,0,1.516937603,,,,,,0,-6.237992323,,,,,,,,1.5-2.5 h,0.7,Goserelin; histrelin; leuprolide; triptorelin,Hepatic imoairement,Category B3,Use with caution
Naloxegol (oxalate),Laxative,Neuroactive ligand-receptor interaction,OPRM1,opioid receptor antagonist,,,,741.828,1.0191,14,4,24,201.37,5,14.12,-0.16,,,13.22,,,,0,10.61971908,0,0,Inactive,0,-0.753420405,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.202832212,0,0,Inactive,Inactive,0,-0.022711248,,,,,,0,2.32226964,,,,,,,~4.2%,6-11 h,,Abametapir; atazanavir; bosentan; carbamazepine; chloramphenicol; clarithromycin; cobicistat; conivaptan; dabrafenib; darunavir; dexamethasone; elvitegravir/cobicistat/emtricitabine/tenofovir DF; enzalutamide; eslicarbazepine acetate; etravirine; fosamprenavir; fosphenytoin; grapefruit; idelalisib; imatinib; indinavir; isoniazid; itraconazole; ketoconazole; lopinavir; mifepristone; mitotane; nafcillin; nefazodone; nelfinavir; nevirapine; nicardipine; oxcarbazepine; pentobarbital; phenobarbital; phenytoin; posaconazole; primidone; quinidine; ribociclib; rifabutin; rifampin; rifapentine; ritonavir; saquinavir St John's Wort ;tipranavir,Hypersensitivity; GI obstruction,NA,Not recommended
Naratriptan (hydrochloride),"Antimigraine, Vasoconstrictor,","Neuroactive ligand-receptor interaction, Seratonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",serotonin receptor agonist,,,,371.934,2.4906,3,2,5,65.2,0,-4.68,0.16,,,3.72,,,,39.81071706,-43.8071261,39.8107,44.6791,Inconclusive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.01036248,0,0,Inactive,Inactive,0,-3.71195786,,,,,,0,-14.89597196,,,,,,,28%-31%,5-8 h,0.74,Almotriptan; bromocriptine; cabergoline; dihydroergotamine; dihydroergotamine intranasal; eletriptan; ergoloid mesylates; ergotamine; frovatriptan; methylergonovine; rizatriptan; sumatriptan; sumatriptan intranasal; zolmitriptan,Hypersensitivity; hepatic or renal impairment; Ischemic heart disease; uncontrolled hyoertention,Category B3,Not recommended
Butenafine (Hydrochloride),Antifungal,Steroid biosynthesis,SQLE,fungal squalene epoxidase inhibitor,,,,353.937,6.1911,1,0,4,3.24,0,-2.45,-0.08,0.4285,,5.772,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,None,Hypersensitivity,Category C,Use with caution
Cromolyn (sodium),"Antiallergic, Antiasthmatic",NA,,,,,,512.334,-6.5469,11,1,8,179.37,0,1.09,0.02,0.06696,,28.47,,,,0,2.266314145,0,0,Inactive,0,-2.68027481,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.735099977,0,0,Inactive,Inactive,0,-0.658416969,,,,,,0,-28.75961186,,,,,,,,1.3 h,0.01,NA,Hypersensitivity,Category B1,Use with caution
Ropinirole (hydrochloride),Antiparkinsonian,"Neuroactive ligand-receptor interaction, Dopaminergic synapse","ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",dopamine receptor agonist,,,,296.842,3.2675,2,1,7,32.34,0,0.37,0.2,-0.01531,,-0.3156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40%,6 h,45-55%,None,Hypersensitivity,Category B3,Not recommended
Prucalopride (succinate),Prokinetic,"Serotonergic synapse, Neuroactive ligand-receptor interaction",HTR4,serotonin receptor agonist,,,,485.965,2.0236,7,4,9,151.42,0,,-0.02,,,29.32,,,,0,0.935088864,,,,0,0,,,,,,,,,,,,,,,,0,14.79270845,,,,,,0,-15.17516307,,,,,,,30%,18-20 h,Reaches maximum plasma concentration of 3.79ng/ml with a tmax of 2.77 hours after initial administration,None,Hypersensitivity,Category B1,Not recommended
Pitolisant (hydrochloride),Nootropic,Neuroactive ligand-receptor interaction,HRH3,histamine receptor antagonist,,,,332.315,4.587,2,0,8,12.47,0,-7.2,0.19,,,13.59,,,,7.943282347,-93.81849103,31.6228,76.3846,Inconclusive,0,-66.55218849,0,0,Inactive,Inactive,39.81071706,-17.39072091,39.8107,59.6482,Inconclusive,39.81071706,-11.49372957,39.8107,38.4222,Inconclusive,Cytotoxic,14.12537545,30.5982577,,,,,,0,-2.64570426,,,,,,,91-96%,10-12 h,0.9,None,Hyoersensitivity; Hepatic impairement,NA,Use with caution
Sertaconazole (nitrate),Antifungal,Steroid biosynthesis,,sterol demethylase inhibitor,,,5.075,500.791,6.6684,6,1,6,90.42,1,88.93,-0.15,-0.4284,,7.058,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,>99%,,,NA,Hypersensitivity,NA,Use with caution
Esmolol (hydrochloride),Antiarrhythmic,"Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes",ADRB1,adrenergic receptor antagonist,,,,331.84,1.9517,5,2,9,67.79,1,-0.79,-0.02,0.0536,,1.827,,,,6.309573445,-18.4583765,6.3096,55.6967,Inconclusive,0,-10.99280407,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-40.76514073,0,0,Inactive,Inactive,0,5.11311629,,,,,,0,-14.14222148,,,,No,,,55%,Distribution half-life: 2 mins; elimination half life: 9 mins,,None,Hypersensitivity; Sinus bradyvadia; Asthma; ,Category C,Not recommended
Sodium Picosulfate,Laxative,NA,,,,,,481.415,-4.0522,9,0,7,145.75,0,0.17,-0.06,,,2.289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.4 h,,None,Hypersensitivity; renal impairment; GI obstruction; toxic colitis,NA,NA
Valacyclovir (hydrochloride),Antiviral,DNA synthesis/replication,,,,,,360.802,-0.3758,9,3,7,151.14,1,-3.85,0.13,0.01019,,-4.848,,,,39.81071706,-53.01135434,39.8107,66.7301,Inconclusive,0,0.285630528,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-0.449541765,,,,,,0,-15.30384158,,,,,,,13.5-17.9%,2.5-3.3 h,54.5% ± 9.1%,None,Hypersensitivity,Category B3,Use with caution
Clemastine (fumarate),Antiallergic,"Neuroactive ligand-receptor interaction, Calcium signaling pathway",HRH1,histamine receptor antagonist,,,8.5228,459.97,4.8162,4,2,8,87.07,2,-10.71,0.18,-0.1711,,27.58,,,,10,-67.46410557,10,86.1768,Active,15.84893192,-85.5251403,0,0,Inactive,Inactive,4.466835922,-111.9028805,4.4668,84.5044,Active,22.38721139,-59.42625503,22.3872,53.6275,Inconclusive,Cytotoxic,11.22018454,67.30973208,10,100.279,Active,,,0,-19.10715596,0,0,Inactive,Inactive,,,,,,None,Asthma; hypersensitivity; nursing women,Category A,Use with caution
Phenylephrine (hydrochloride),"Midriatic, Vasoconstrictor,","Neuroactive ligand-receptor interaction, Calcium signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D",adrenergic receptor agonist,0.86,,,203.669,1.0668,3,3,3,52.49,1,-0.74,-0.08,,,28.74,,,,12.58925412,-22.65280341,12.5893,35.5295,Inconclusive,0,-28.79422722,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-33.16950157,0,0,Inactive,Inactive,0,-1.81212656,,,,,,0,-13.80615341,,,,,,,Data regarding the protein binding of phenylephrine in serum is not readily available,Intravenous phenylephrine has an effective half life of 5 minutes and an elimination half life of 2.5 hours.,0.38,Iobenguane I 123; isocarboxazid; linezolid; phenelzine; procarbazine; selegiline transdermal; tranylcypromine,None,Category B2,Use with caution
Allopurinol riboside,Anti-gout,"Purine metabolism, Peroxisome",,"anti-leishmanial agent, phosphorylase inhibitor",,,,268.229,-2.2689,8,4,2,133.49,4,-5.55,0,,,16.09,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Allopurinol and oxypurinol are only negligibly bound to plasma proteins,"The plasma half-life of allopurinol is 1-2 hours, due to its rapid renal clearance",,None,Hypersensitivity,NA,NA
Bromocriptine (mesylate),Antiparkinsonian,"Neuroactive ligand-receptor interaction, Dopaminergic synapse, Prolactin signaling pathway,","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7",dopamine receptor agonist,,,,750.713,2.6968,8,4,5,172.58,6,,,-0.08637,,,,,,31.6227766,-10.93051803,31.6228,38.9024,Inconclusive,0,-6.078888968,0,0,Inactive,Inactive,28.18382931,-56.97996502,28.1838,116.056,Inconclusive,0,-0.114770419,0,0,Inactive,Inactive,,,,,,,,,,,,,,,,90-96% bound to serum albumin,2-8 hours,0.06,Almotriptan; chloramphenicol; eletriptan; frovatriptan; glyceryl trinitrate pr; lopinavir; naratriptan; nitroglycerin IV; nitroglycerin sublingual; nitroglycerin topical; nitroglycerin transdermal; nitroglycerin translingual; posaconazole; sumatriptan; sumatriptan intranasal; zolmitriptan,Hyoersensitivity; uncontrolled hypertention; hyperprolactinemia; CAD,Category A,Not recommended
Terbinafine hydrochloride,Antifungal,Steroid biosynthesis,SQLE,fungal squalene epoxidase inhibitor,,,,327.899,5.2991,1,0,4,3.24,0,-5.95,0.04,,,6.375,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Terbinafine is >99% bound to proteins in plasma, mostly to serum albumin, high and low density lipoproteins, and alpha-1-acid glycoprotein to a lesser extent.","Oral terbinafine has an effective half life of approximately 36 hours. However, the terminal half life ranges from 200-400 hours as it distributes into skin and adipose tissue. 1% topical terbinafine's half life increases over the first seven days from approximately 10-40 hours.",~40%,None,Hypersensitivity; Chronic/active liver disease,Category B1,Not recommended
Cefuroxime axetil,Antibacterial,Peptidoglycan biosynthesis,,bacterial cell wall synthesis inhibitor,,,,510.481,-0.1683,12,2,9,189.06,3,1.31,-0.13,0.1456,,17.81,,,,35.48133892,-20.09463568,35.4813,65.1073,Inconclusive,0,13.50182714,0,0,Inactive,Inactive,0,8.378322507,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,1.377925043,,,,,,0,-9.963139297,,,,,,,50% to serum protein,Approximately 80 minutes following intramuscular or intravenous injection.,"37%
 52% (fed conditions)",NA,NA,Category B1,Use with caution
GLICLAZIDE,Antidiabetic,"ABC transporters, Insulin secretion",,"ATP channel blocker, insulin secretagogue",,,6.22,323.418,1.62982,4,2,3,78.51,2,,,0.09396,0.08068,,,,,0,9.976098663,0,0,Inactive,0,-57.82743515,0,0,Inactive,Inactive,0,-24.36339043,0,0,Inactive,0,-90.60360853,0,0,Inactive,Inactive,0,-1.751943978,,,,,,0,18.02008076,,,,,,,"94%, highly bound to plasma proteins",16.40 hours,97%,NA,NA,Category C,Not recommended
TRICLABENDAZOLE,Anthelmintic,NA,DNMT1,microtubule inhibitor,,,,359.665,6.0373,3,1,3,37.91,0,-0.51,1.38,0.1948,0.18,20.44,,,,,,,,,,,,,,,,,,,,,,,,,,0,3.652468653,,,,,,0,-13.93024781,,,,,,,,"The plasma elimination half-life (t1/2) of triclabendazole, the sulfoxide and sulfone metabolites in human is about 8, 14, and 11 hours, respectively.[FDA label]",,None,Hypersensitivity,NA,No sufficient information is available
CARBIMAZOLE,Antithyroid,Thyroid hormone synthesis,TPO,,,,,186.236,1.56069,5,0,1,36.16,0,1.57,0.05,0.0747,0.2511,5.31,,,,0,-5.466777154,0,0,Inactive,0,10.58178326,0,0,Inactive,Inactive,0,-8.356233011,0,0,Inactive,0,-2.460415392,0,0,Inactive,Inactive,0,8.449704386,,,,,,0,-11.21320167,,,,,,,,,0%,NA,NA,Category C,Not recommended
MECAMYLAMINE HYDROCHLORIDE,Antihypertensive,"Neuroactive ligand-receptor interaction, Cholinergic synapse","CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB4",acetylcholine receptor antagonist,,,7,203.757,2.8424,1,1,1,12.03,3,,0.56,,0.1041,16.11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40%,,99%,None,Hypersensitivity; coronary insufficiency; glaucoma; uremia,Category C,Use with caution
BUSPIRONE HYDROCHLORIDE,Anxiolytic,"Neuroactive ligand-receptor interaction, Serotonergic synapse, Dopaminergic synapse","DRD2, HTR1A",serotonin receptor agonist,,,7.602,421.973,2.51,6,0,6,69.64,0,,,,0.1391,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"In a single-dose pharmacokinetic study of 14C-labeled buspirone, the average elimination half-life of unchanged buspirone following administration of single doses ranging from 10 to 40 mg was about 2 to 3 hours.[L4478]",3.90%,Isocarboxazid; linezolid; phenelzine; procarbazine; selegiline transdermal; tranylcypromine,Hypersensitivity,Category B1,Not recommended
RIMANTADINE HYDROCHLORIDE,Antiviral,NA,,RNA synthesis inhibitor,,,,215.768,2.9718,1,1,1,26.02,5,,0.05,,0.1024,10.22,,,,35.48133892,-35.52676798,35.4813,80.1774,Inconclusive,0,10.80259426,0,0,Inactive,Inactive,0,-51.88516128,0,0,Inactive,0,-69.13201711,0,0,Inactive,Inactive,0,0.70849444,,,,,,0,-18.83233405,,,,,,,Approximately 40% over typical plasma concentrations.,25 to 30 hours in young adults (22 to 44 years old). Approximately 32 hours in elderly (71 to 79 years old) and in patients with chronic liver disease. Approximately 13 to 38 hours in children (4 to 8 years old).,,None,Hypersensitivity,Category C,Not recommended
GLIPIZIDE,Antidiabetic,"ABC transporters, Insulin secretion","ABCC4, ABCC8, KCNJ10, KCNJ11, PPARG",,,,3.8761,445.545,2.07812,6,3,7,130.15,0,-4.06,-0.04,0.03796,0.0999,5.804,,,,0,-29.88856501,0,0,Inactive,0,-4.444033117,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.406938717,0,0,Inactive,Inactive,0,2.814606263,,,,,,0,-16.1140697,,,,,,,"Glipizide is about 98-99% bound to serum proteins, with albumin being the main plasma protein",3.30 hours,95%,None,Hypersensitivity; sulfa allergy; Type 1 diabetes; Diabetic ketoacidosis with or without coma,Category C,Use with caution
XYLOMETAZOLINE HYDROCHLORIDE,Vasoconstrictor,"Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",adrenergic receptor agonist,,,,280.843,3.56694,2,1,2,24.39,0,,-0.09,,,13.6,,,,3.981071706,-68.16613722,3.9811,64.4438,Inconclusive,0,0,0,0,Inactive,Inactive,0,-1.193966799,0,0,Inactive,0,0.571601192,0,0,Inactive,Inactive,14.12537545,21.83646525,,,,,,0,-32.38664064,,,,,,,,,,Isocarboxazid; linezolid; phenelzine; selegiline transdermal; tranylcypromine,Heart diseases,Category C,No sufficient information is available
MECLIZINE HYDROCHLORIDE,Anti-emetic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",NR1I3,constitutive androstane receptor (CAR) agonist,,,,463.88,6.39922,2,0,5,6.48,1,,1.33,,,12.5,,,,6.309573445,-11.01066177,0,0,Inactive,0,6.025062211,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-4.072000475,,,,,,0,-10.75000337,,,,,,,,Meclizine has a plasma elimination half-life of about 5-6 hours in humans.[L6772],,NA,Hypersensitivity,Category B,Use with caution
CYCLOSERINE (D),Antibacterial (tuberculostatic),"Peptidoglycan biosynthesis, D-Alanine metabolism",GRIN1,bacterial cell wall synthesis inhibitor,,,,102.093,-1.6249,3,2,0,64.35,1,-2.21,0.17,1.427,,23.75,,,,0,-18.79928126,0,0,Inactive,0,-4.58351177,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.616934082,0,0,Inactive,Inactive,0,-4.81934027,,,,,,0,-18.34068652,,,,,,,,"Half-life in patients with normal renal function is 10 hours, and is prolonged in patients with impaired renal function.",80%,NA,Hypersensitivity; Severe renal dysfunction; seizures,Category C,Use with caution
CARTEOLOL HYDROCHLORIDE,"Antiglaucoma, Antiarrhythmic, Antihypertensive","Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, cAMP signaling pathway","ADRB1, ADRB2, ADRB3",adrenergic receptor antagonist,,,,328.84,2.1209,4,3,5,70.59,1,,,,0.1646,,,,,0,-10.74187383,0,0,Inactive,0,-31.56538022,0,0,Inactive,Inactive,0,3.405700329,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0.425642004,,,,,,0,-23.93488554,,,,,,,,4.70 hours,88%,NA,"Asthma, uncompensated CHF, any beta-blocker side effects, hypersensitivity, severe COPD, 2°/3° AV block, cardiogenic shock",NA,Not recommended
DICYCLOMINE HYDROCHLORIDE,Antispasmodic,"Calcium signaling pathway, Neuroactive ligand-receptor interaction, cholinergic synapse, cAMP signaling pathway",,,,,,345.955,4.824,3,0,7,29.54,0,,,,0.1568,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The mean plasma elimination half life is approximately 1.8 hours.[A182525,L7967]",,None,Hypersensitivity to dicyclomine or any anticholinergic drugs; Closed-angle glaucoma; Myasthenia gravis; Hemorrhage with cardiovascular instability; Paralytic ileus; Breast-feeding; Intestinal atony of elderly/debilitated patients; Toxic megacolon; GI obstruction; Obstructive uropathy; Severe ulcerative colitis; Reflux esophagitis,Category B1,Not recommended
DIMENHYDRINATE,"Anti-emetic, Antivertigo","Calcium signaling pathway, Neuroactive ligand-receptor interaction",HRH1,histamine receptor antagonist,,,4.0757,469.973,2.9679,7,1,6,85.15,0,-1.08,0,1.153,,16.23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,98 to 99%.,1 to 4 hours,,None,Hypersensitivity; Asthma; neonates; nursing women,Category A,Use with caution
ACYCLOVIR,Antiviral,DNA synthesis/replication,PNP,DNA polymerase inhibitor,,,,225.208,-1.3318,7,3,4,119.05,0,8.75,0.04,0.1444,0.1075,6.729,,,,0,0,0,0,Inactive,0,-7.013668247,0,0,Inactive,Inactive,0,6.837535791,0,0,Inactive,0,-23.22050268,0,0,Inactive,Inactive,0,3.824972343,,,,,,0,6.759000897,,,,,,,Acyclovir is 9-33% protein bound in plasma.,2.50 hours,22.50%,None,Hypersensitivity,Category B3,Use with caution
TETRAHYDROZOLINE HYDROCHLORIDE,Vasoconstrictor,"Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction",GNA15,adrenergic receptor agonist,,,4.5243,236.746,2.53,2,1,1,24.39,1,,-0.05,,0.1519,17.25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,None,Hypersensitivity,Category C,No sufficient information is available
PROPANTHELINE BROMIDE,Antispasmodic,"Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Gastric acid secretion","CHRM1, CHRM2, CHRM3, CHRM4",acetylcholine receptor antagonist,,,,448.401,1.7348,3,0,6,35.53,0,,-0.02,,0.1356,10.7,,,,0,-18.54992209,0,0,Inactive,0,5.593244844,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,10.09246769,0,0,Inactive,Inactive,0,-2.874992878,,,,,,0,-11.76271043,,,,,,,,,,None,"Hypersensitivity; Closed-angle glaucoma, myasthenia gravis, hemorrhage w/ cardiovascular instability, paralytic ileus, intestinal atony of elderly/debilitated pt, obstructive uropathy, toxic megacolon, GI obstruction",Category B2,Use with caution
ETHIONAMIDE,Antibacterial (tuberculostatic),NA,,mycolic synthesis inhibitor,,,,166.249,1.2782,2,1,2,38.91,0,-1.84,-0.13,0.1212,0.1784,18.18,,,,0,3.664284582,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-12.94469923,0,0,Inactive,0,-8.556702746,0,0,Inactive,Inactive,0,-4.723959701,,,,,,0,-16.97779043,,,,,,,Approximately 30% bound to proteins.,2 to 3 hours,80%,None,Hypersensititvity; severe hepatic dysfunction,Category C,Use with caution
GLYBURIDE,Antidiabetic,"ABC transporters, Insulin secretion","ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1","ATP channel blocker, insulin secretagogue, sulfonylurea",,,6.6575,494.013,3.6417,5,3,8,113.6,0,-1.61,-0.07,0.2282,,13.62,,,,0,-36.89466252,0,0,Inactive,0,8.352390454,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-2.174900403,,,,,,0,-15.87166242,,,,,,,Glyburide is 99.9% bound to protein in plasma with >98% accounted for by binding to serum albumin.,2.20 hours,82%,Bosentan,Hypersensitivity; sulfa allergy; Type 1 diabetes; Diabetic ketoacidosis with or without coma,NA,Use with caution
CHLORZOXAZONE,Skeletal muscle relaxant,NA,"KCNMA1, KCNN4",bacterial 30S ribosomal subunit inhibitor,,,4.52,169.567,1.7745,2,1,0,46,0,-2.41,-0.11,0.06344,0.18,25.61,,,,0,1.888942275,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,1.673643933,0,0,Inactive,0,7.506901628,0,0,Inactive,Inactive,0,3.311931149,,,,,,0,-8.490194639,,,,,,,,,,None,Hypersensititvity,NA,NA
ALLOPURINOL,Anti-gout,"Purine metabolism, Peroxisome",XDH,xanthine oxidase inhibitor,,,5.699,136.114,-0.3538,3,2,0,74.43,0,-27.22,0.35,0.1167,0.02121,15.51,,,,0,-390.9998703,0,0,Inactive,14.12537545,-258.1436537,0,0,Inactive,Inactive,0,-416.4756609,0,0,Inactive,0,-250.3642621,0,0,Inactive,Inactive,0,-1.430080843,,,,,,0,-10.15203611,,,,,,,Allopurinol and oxypurinol are only negligibly bound to plasma proteins,0.80 hours,53%,None,Hypersensitivity,Category B2,Not recommended
PHENYLEPHRINE HYDROCHLORIDE,"Midriatic, Vasoconstrictor","Calcium signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D",adrenergic receptor agonist,,,5.9,203.669,1.0668,3,3,3,52.49,1,,-0.07,,0.03283,17.14,,,,12.58925412,-22.65280341,12.5893,35.5295,Inconclusive,0,-28.79422722,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-33.16950157,0,0,Inactive,Inactive,0,-1.81212656,,,,,,0,-13.80615341,,,,,,,,"Intravenous phenylephrine has an effective half life of 5 minutes and an elimination half life of 2.5 hours.[A187379,L9416,L9410]",35%,Iobenguane I 123; isocarboxazid; linezolid; phenelzine; procarbazine; selegiline transdermal; tranylcypromine,None,Category B2,Use with caution
ETHAMBUTOL HYDROCHLORIDE,Antibacterial (tuberculostatic),NA,ABCC4,bacterial cell wall synthesis inhibitor,,,3.876,277.236,0.551,4,4,9,64.52,2,,-0.14,,,4.24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ethambutol is 20-30% bound to protein in plasma,3.10 hours,77%,None,Hypersensitivity; Known optic neuritis,Category A,Recommended
PYRIMETHAMINE,Antimalarial,"Pyrimidine metabolism, Folate biosynthesis","DHFR, SLC47A1",dihydrofolate reductase inhibitor,,,,248.717,2.5238,4,2,2,77.82,0,57.63,9.02,0.7421,0.2473,15.45,,,,39.81071706,-45.50275512,39.8107,45.106,Inconclusive,39.81071706,-30.35835158,39.8107,51.4894,Inconclusive,Cytotoxic,39.81071706,-22.9004696,39.8107,78.5461,Inconclusive,39.81071706,-22.31717971,39.8107,88.4059,Inconclusive,Cytotoxic,11.22018454,31.4146497,,,,,,6.309573445,-86.57631335,,,,,,,87%,140 hours,90%,Eliglustat,Hypersensitivity; Megaloblastic or folate-deficiency anemia,Category B3,Not recommended
PRAZIQUANTEL,Anthelmintic ,NA,ABCC4,,,,3.8761,312.413,2.5349,2,0,1,40.62,1,,,0.2207,,,,,,0,-121.9808706,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-95.39783475,0,0,Inactive,0,-9.730679791,0,0,Inactive,Inactive,0,-0.873227038,,,,,,0,-23.06392689,,,,,,,80 to 85%,0.8-1.5 hours (in serum),7%,Bosentan; carbamazepine; dabrafenib; dexamethasone; efavirenz; enzalutamide; eslicarbazepine acetate; etravirine; fosphenytoin; mitotane; nafcillin; nevirapine; oxcarbazepine; pentobarbital; phenobarbital; phenytoin; primidone; rifabutin; rifampin; rifapentine,Hypersensitivity; Intraocular cysticercosis,Category B1,Not recommended
GUAIFENESIN,"Antitussive, Expectorant",NA,ABCB11,,,,3,198.218,0.4272,4,2,5,58.92,1,,,0.07395,0.2008,,,,,0,-163.6664449,0,0,Inactive,0,2.68545671,0,0,Inactive,Inactive,0,-73.80624427,0,0,Inactive,0,2.548150528,0,0,Inactive,Inactive,0,-2.35940406,,,,,,0,-40.28008734,,,,,,,,"The half-life in plasma observed for guaifenesin is approximately one hour [A177676, L6079, L6100, F4522, F4525].",,None,Hyersensitivity,Category A,Not recommended
SULFAMETHIZOLE,Antibacterial,Folate biosynthesis,CYP3A4,,,,3.0777,270.339,1.22952,6,2,3,97.97,0,13.56,0.11,0.01199,0.1221,14.03,,,,0,-69.33899868,0,0,Inactive,0,1.808839996,0,0,Inactive,Inactive,0,-101.6746949,0,0,Inactive,0,-1.252950462,0,0,Inactive,Inactive,0,10.36194773,,,,,,0,-5.116155161,,,,,,,98-99%,3-8 hours,,NA,NA,Category C,NA
ALLANTOIN,"Anti-inflammatory,",NA,,,,,,158.117,-2.1798,3,4,1,113.32,1,,,0.03873,0.1646,,,,,0,-153.0303877,0,0,Inactive,0,-1.820218614,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,9.772898339,,,,,,0,-10.89733528,,,,,,,,1 to 2.5 h,,NA,NA,NA,NA
BETHANECHOL CHLORIDE,Prokinetic,"Neuroactive ligand-receptor interaction, Cholinergic synapse, Gastric acid secretion","CHRM1, CHRM2, CHRM3, CHRM4",acetylcholine receptor agonist,,,,196.678,-2.8196,2,1,3,52.32,1,,,,0.07337,,,,,0,-4.509911624,0,0,Inactive,0,-7.708451783,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-10.02456742,0,0,Inactive,Inactive,0,-0.873627619,,,,,,0,-21.82276324,,,,,,,,,,None,Hypersensitivity; hyperthyroidism; peptic ulcer; asthma; bradycardia; hypotension; AV conduction defects; CAD vasomotor instability; vagotonia; epilepsy; Parkinsonism; GI of GU obstruction; weak bladder wall; recent urinary bladder surgery; GI resection or anastomosis; spastic GI disturbances; HTN; obstructive pulmonary disease,Category B2,Use with caution
PAPAVERINE HYDROCHLORIDE,"Antispasmodic, Smooth muscle relaxant, Vasodilator","Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway","PDE10A, PDE4B, PDE5A",phosphodiesterase inhibitor,,,7.7695,375.852,4.2818,5,0,6,49.81,0,,-0.24,,0.03666,17.4,,,,6.309573445,-165.60092,,,,7.943282347,-57.35432358,,,,,,,,,,,,,,,,0,-8.101621942,,,,,,0,-30.76905128,,,,,,,~90%,1.80 hours,28%,None,Hypersensitivity; Complete AV block,Category B3,Use with caution
OXYMETAZOLINE HYDROCHLORIDE,Vasoconstrictor,"Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",adrenergic receptor agonist,,,,296.842,3.27254,3,2,2,44.62,0,,0.07,,0.2228,24.54,,,,0,-11.59692265,0,0,Inactive,0,4.77084277,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.092416932,0,0,Inactive,Inactive,0,-2.828628313,,,,,,0,-2.257233181,,,,,,,56.7-57.5%,,11%,None,None,NA,Use with caution
PROBUCOL,Antihyperlipidemic,NA,"ABCA1, ABCB11, CES1",atherogenesis inhibitor,,,,516.857,9.9083,4,2,4,40.46,0,2.84,0.59,0.2869,,26.51,,,,7.079457844,-89.88755971,7.0795,36.9486,Inconclusive,0,4.879739045,0,0,Inactive,Inactive,0,-120.256949,0,0,Inactive,0,7.13969797,0,0,Inactive,Inactive,0,7.335153905,,,,,,0,-18.44881848,,,,,,,,"Ranges from 12 h - 500 h, the longest half-life probably being in adipose tissue.",5%,NA,NA,Category B1,NA
CHLORPROPAMIDE,"Antidiabetic, Hypoglycemic","ABC transporters, Insulin secretion","ABCC8, ABCC3, KCNJ10",ATP channel blocker,,,3.8761,276.745,1.7379,3,2,4,75.27,0,4.33,0.09,0.09227,0.2087,13.38,,,,0,-45.49609625,0,0,Inactive,0,12.11952663,0,0,Inactive,Inactive,0,-73.05797368,0,0,Inactive,0,0.21930055,0,0,Inactive,Inactive,0,0.48682844,,,,,,0,-24.50570053,,,,,,,Highly bound to plasma,46 hours,95%,Dronabinol,"Type I diabetes; Diabetes ketoacidosis; Hypersensitivity, sulfa allergy; Severe renal impairment",Category C,Use with caution
PYRAZINAMIDE,Antibacterial (tuberculostatic),NA,FASN,fatty acid synthase inhibitor,,,,123.115,-0.4245,3,1,1,68.87,0,44.3,0,0.01701,0.1788,14.28,,,,0,-30.78405555,0,0,Inactive,0,9.294300246,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,10.61496308,0,0,Inactive,Inactive,0,-3.083092535,,,,,,0,-10.19210349,,,,,,,~10%,9-10 hours (normal conditions),90%,None,Hepatic damage; acute gout; hypersensitivity,Category B2,Use with caution
BENOXINATE HYDROCHLORIDE,Anesthetic (topical),Dopaminergic synapse,SCN1A,,,,5.54,344.883,3.3681,5,1,10,64.79,0,,,,0.147,,,,,14.12537545,-64.71148692,0,0,Inactive,0,0.87606377,0,0,Inactive,Inactive,39.81071706,-13.03997395,39.8107,46.9747,Inconclusive,35.48133892,-10.96066512,35.4813,35.3339,Inconclusive,Cytotoxic,0,4.143924367,,,,,,0,-33.54502775,,,,,,,,,,None,Hypersensitivity,NA,NA
PROBENECID,"Anti-gout, Uricosuric",NA,"PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1",uricosuric blocker,,,5.2007,285.365,2.1955,3,1,7,74.68,0,1.35,0.08,0.2093,,15.12,,,,0,-42.62226298,0,0,Inactive,0,2.200630514,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,7.699700188,0,0,Inactive,Inactive,0,0.978674226,,,,,,0,-35.35218372,,,,,,,75-95%,5.90 hours,99%,None,"Uric acid kidney stones, acute gouty arthritis; Hypersensitivity; Blood dyscrasias",Category B2,Use with caution
TOLBUTAMIDE,"Antidiabetic, Hypoglycemic","ABC transporters, Insulin secretion","ABCC8, ABCC4, KCNJ1, KCNJ11, KCNJ8",ATP channel blocker,,,3.8761,270.354,1.78302,3,2,5,75.27,0,3.6,0.19,-0.01112,,21.67,,,,0,-1.606396107,0,0,Inactive,0,2.953090091,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-3.500377777,0,0,Inactive,Inactive,0,-2.976245871,,,,,,0,-14.98582329,,,,,,,95%,7 hours,85%,None,"Hypersensitivity, sulfa allergy; Type I diabetes, diabetic ketoacidosis",Category C,Use with caution
NAPHAZOLINE HYDROCHLORIDE,Vasoconstrictor,Neuroactive ligand-receptor interaction,"ADRA1A, ADRA2A, ADRA2B",adrenergic receptor agonist,,,11.9586,246.741,2.8058,2,1,2,24.39,0,,0.52,,0.002061,12.64,,,,0,-10.96023277,0,0,Inactive,0,3.477288401,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-3.682046748,,,,,,0,-1.014273075,,,,,,,,Half life has not been determined but effects last for 4 to 8 hours.,,None,"Heart disease (incr BP, HR, palpitations); Narrow angle glaucoma",NA,
TOLAZAMIDE,"Antidiabetic, Hypoglycemic","ABC transporters, Insulin secretion","ABCC8, KCNJ1, KCNJ10, KCNJ11",ATP channel blocker,,,,311.407,1.77392,4,2,3,78.51,0,8.18,-0.15,0.0131,0.157,32.71,,,,0,-21.76094511,0,0,Inactive,0,8.29626065,0,0,Inactive,Inactive,0,2.448159297,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-2.03377317,,,,,,0,-21.41046166,,,,,,,,7 h,,None,Hypersensitivity; sulfa allergy; diabetic ketoacidosis; Type 1 diabetes,Category C,Not recommended
NALIDIXIC ACID,Antibacterial,DNA synthesis/replication,,bacterial DNA gyrase inhibitor,,,,232.239,1.42302,4,1,2,72.19,0,-0.44,0.12,,0.03233,12.92,,,,0,-5.277969596,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-9.380491449,,,,,,0,-32.77548898,,,,,,,93%,"1.1 to 2.5 hours in healthy adult patients, and up to 21 hours in patients with impaired renal function.",96%,NA,NA,Category A,Use with caution
CLOFIBRATE,Antihyperlipidemic,"PPAR signaling pathway, Adipocytokine signaling pathway","LPL, PPARA",PPAR receptor agonist,,,4.25,242.702,3.0605,3,0,4,35.53,0,,,0.08504,0.007924,,,,,0,-42.73835177,0,0,Inactive,0,1.45023801,0,0,Inactive,Inactive,0,-5.232052235,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,9.989019192,,,,,,0,-14.01831037,,,,,,,95-97%,18-22 h,95%,NA,NA,Category B1,NA
NEOSTIGMINE BROMIDE,Parasympathomimetic,"Glycerophospholipid metabolism, Cholinergic synapse",ACHE,acetylcholinesterase inhibitor,,,10.3665,303.2,-1.0523,2,0,2,29.54,0,,-0.14,,0.1096,12.59,,,,0,-24.4913318,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.779249603,0,0,Inactive,Inactive,0,10.70682813,,,,,,0,-1.074971516,,,,,,,,1.30 hours,2%,None,Hypersensitivity,Category B2,Use with caution
METHOCARBAMOL,Skeletal muscle relaxant,NA,CA1,muscle relaxant,,,7.6,241.243,0.5302,5,2,6,91.01,1,1.12,-0.31,0.09817,,10.07,,,,0,-97.80945854,0,0,Inactive,0,-7.605414599,0,0,Inactive,Inactive,0,-6.760039393,0,0,Inactive,0,-14.84166346,0,0,Inactive,Inactive,0,1.871579725,,,,,,0,-23.49119365,,,,,,,Methocarbamol is 46-50% protein bound in healthy patients and 47.3-48.9% protein bound in hemodialysis patients,The elimination half life is 1.14 hours in healthy subjects and 1.24 hours in subjects with renal insufficiency.[A636] Older studies report half lives of 1.6-2.15 hours.[A178366],,None,Renal impairement,Category B3,Use with caution
ACETAZOLAMIDE,Antiglaucoma,Proximal tubule bicarbonate reclamation,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",carbonic anhydrase inhibitor,,,8.2365,222.251,-0.8561,6,2,2,115.04,0,-4.52,-0.12,0.04502,0.1016,9.824,,,,0,-80.91885086,0,0,Inactive,0,-7.430385095,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.351592045,0,0,Inactive,Inactive,0,1.814488279,,,,,,0,-20.63394837,,,,,,,98%,13 hours,99%,None,Hypokalemia; Hyponatremia; Hyperchloremic acidosis; Hypersensitivity to acetazolamide or sulfa; Liver disease,Category B3,Use with caution
SULFADIAZINE,Antibacterial,Folate biosynthesis,"CA1, CA2, CA6",,,,4.5817,250.283,0.8596,5,2,3,97.97,0,-3.32,-0.11,-0.0006413,,15.43,,,,0,2.174276948,0,0,Inactive,0,-3.885093,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-7.111555396,0,0,Inactive,Inactive,0,-13.92697388,,,,,,0,-10.30040041,,,,,,,,7 hours,90%,None,Should not be used for group A beta-hemolytic strep infections,Category C,Use with caution
PHENTOLAMINE HYDROCHLORIDE,Vasodilator,"Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",adrenergic receptor antagonist,,,8.9586,317.82,3.26222,4,2,4,47.86,0,,0.13,,0.06841,14.21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.50 hours,,None,Hypersensitivity; MI or other CAD,Category B1,Not recommended
DOXYLAMINE SUCCINATE,Anti-allergic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",HRH1,histamine receptor antagonist,,,,388.464,2.8591,5,2,9,99.96,1,3.91,-0.02,-0.01157,,2.832,,,,4.466835922,-51.95276167,4.4668,40.9754,Inconclusive,0,1.688250662,0,0,Inactive,Inactive,0,-5.676281589,0,0,Inactive,0,5.992165961,0,0,Inactive,Inactive,0,-0.716804248,,,,,,0,-32.36344052,,,,,,,,10 hours,,None,Hypersensitivity,Category A,Not recommended
MEPENZOLATE BROMIDE,"Antispasmodic, Anti-ulcerative","Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Gastric acid secretion",CHRM3,acetylcholine receptor antagonist,,,,420.347,-0.2915,3,1,4,46.53,1,,,,0.1869,,,,,0,-9.325692207,0,0,Inactive,0,-3.867056641,0,0,Inactive,Inactive,0,-29.44461974,0,0,Inactive,0,9.452990098,0,0,Inactive,Inactive,0,1.113614768,,,,,,0,1.941499028,,,,,,,,,,NA,NA,NA,Use with caution
Gefitinib (ZD1839),Antineoplastic,"MAPK signaling pathway, ErbB signaling pathway,",EGFR,EGFR inhibitor,,,10,446.91,4.2756,7,1,8,68.74,0,18.82,9.07,0.2901,0.178,19.63,,,,12.58925412,-62.77745603,12.5893,99.3085,Active,39.81071706,-30.9409406,39.8107,66.8293,Inconclusive,Cytotoxic,39.81071706,-24.25680411,39.8107,83.1981,Inconclusive,39.81071706,-13.62499036,39.8107,46.7322,Inconclusive,Cytotoxic,0,-10.88521906,,,,,,11.22018454,-120.9162432,,,,,,,90% primarily to serum albumin and alpha 1-acid glycoproteins (independent of drug concentrations).,34 hours,60%,None,None,Category C,Not recommended
Rucaparib (AG-014699 or PF-01367338) phosphate,Antineoplastic,"Apoptosis, Necroptosis, Base excision repair","PARP1, PARP2",PARP inhibitor,,,9.301,421.365,2.0507,3,6,3,134.68,0,4.71,1.02,,,93.3,,,,31.6227766,-24.74618247,,,,0,12.01377064,,,,,,,,,,,,,,,,0,20.55052547,,,,,,0,-12.29281642,,,,,,,"In vitro, the protein binding of rucaparib was 70% in human plasma at therapeutic concentrations. Rucaparib preferentially distributed to red blood cells with a blood-to-plasma concentration ratio of 1.83","Following a single oral dose of 600mg rucaparib, the mean terminal half life (t1/2) was 17-19 hours [FDA Label].",36%; range from 30% to 45%.,Finerenone; isavuconazonium sulfate; lonafarnib; voclosporin,None,NA,Not recommended
ETC-1002,Antidyslipidemia,Citrate cycle (TCA cycle),,,,,5.69,344.492,4.4699,3,3,14,94.83,0,-6.33,0.09,,0.1415,19.18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The plasma protein binding of bempedoic acid and its metabolites is about 99%,The half-life of bempedoic acid ranges between 15 and 24 hours.[A191877] Prescribing information indicates a clearance of 21 hours +/- 11 hours.[L12144],,NA,NA,NA,Not recommended
Nifurtimox,Antiprotozoal,NA,HSPD1,DNA inhibitor,,,3.602,287.297,0.6406,7,0,3,106.02,1,,,0.8408,0.1929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The plasma protein binding of nifurtimox is approximately 42%.[L15361] It is primarily bound to albumin.[A216931],The elimination half-life of nifurtimox ranges from 2.4–3.6 hours.[L15361] A pharmacokinetic study of healthy volunteers and patients with renal failure revealed respective mean half-lives of 2.95 h and 3.95 h.[A217936],,None,Hypersensitivity; alcohol consuption during treatment,NA,Use with caution
Rimegepant,Antimigraine,Neuroactive ligand-receptor interaction,CALCA,calcitonin antagonist,,,10.56,534.567,4.49,7,2,3,119.13,3,2.52,0.23,,0.2662,37.92,,,,,,,,,,,,,,,,,,,,,,,,,,0,6.914579925,,,,,,0,-22.05933578,,,,,,,Rimegepant is approximately 96% plasma protein-bound.[L11971] The specific proteins to which rimegepant binds have not been elucidated.,The elimination half-life in healthy subjects is approximately 11 hours.[L11971],0.64,None,Hypersensitivity,NA,Not recommended
Moxonidine,Antihypertensive,"cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction","ADRA2A, ADRA2B, ADRA2C",imidazoline receptor agonist,,,,241.682,0.81812,6,2,2,71.43,0,,0.05,0.9675,0.157,19.01,,,,0,-1.972047955,0,0,Inactive,0,-4.571446414,0,0,Inactive,Inactive,0,1.899039839,0,0,Inactive,0,2.379901489,0,0,Inactive,Inactive,0,0.060749166,,,,,,0,-28.34341794,,,,,,,About 10% of moxonidine is bound to plasma proteins. [FDA label],2.20 hours,88%,NA,NA,Category B3,Use with caution
Lubiprostone,"Peristaltic accelerator, Softener,",Mineral absorption,CLCN2,chloride channel activator,,,,390.467,4.1525,4,2,14,91.67,3,15.74,0.06,,,4.135,,,,0.316227766,-137.3361044,0.3162,33.381,Inconclusive,0,-0.500699445,0,0,Inactive,Inactive,0,-18.30548514,0,0,Inactive,0,1.110682404,0,0,Inactive,Inactive,0,-6.62631798,,,,,,0,-41.34699071,,,,,,,94%,0.9 to 1.4 hours,,None,Hypersensitivity,NA,use with caution
Capmatinib,Antineoplastic,"Ras signaling pathway, PI3K-Akt signaling pathway",,,,,,412.428,3.429,6,1,4,85.07,0,1.59,1.09,,,8.178,,,,39.81071706,-9.18247318,,,,0,0,,,,,,,,,,,,,,,,0,5.29026748,,,,,,0,-27.65320488,,,,,,,Plasma protein binding is approximately 96% and is independent of drug serum concentration.[L13347],The elimination half-life is 6.5 hours.[L13347],>70%.,None,NA,NA,Not recommended
Cinnarizine,"Anti-emetic, Antivertigo","Calcium signaling pathway, Neuroactive ligand-receptor interaction",,,,,,368.524,5.107,2,0,6,6.48,0,5.27,-0.1,0.6874,0.3702,31.02,,,,1.77827941,-46.72737001,0.7943,37.7759,Inconclusive,0,3.330601675,0,0,Inactive,Inactive,3.16227766,-223.2866898,0,0,Inactive,0,4.823314883,0,0,Inactive,Inactive,0,1.614210273,,,,,,0,-38.41020557,,,,,,,,,,NA,NA,NA,Not recommended
Tedizolid,Antibacterial,Ribosome- protein biosynthesis,,bacterial 50S ribosomal subunit inhibitor,,,,370.344,1.3957,8,1,4,106.26,1,11.24,0.01,,0.1987,14.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Approximately 70 to 90% of tedizolid is bound to human plasma proteins.[L11232, A199050, A199152, A199155]","Tedizolid has a half-life of approximately 12 hours.[L11232, A199140, A7642]",0.91,Cyproheptadiene,NA,NA,Use with caution
Treprostinil,"Anticoagulant, Antihypertensive, Vasodilator","Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation","P2RY12, PPARD, PTGIR",prostanoid receptor agonist,,,8.72,390.52,3.5832,4,3,10,86.99,5,,0.12,,,12.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Human plasma protein binding is approximately 91% in in vitro concentrations ranging from 330 to 10,000 &micro;/L.",0.82 hours,~100 % (subcutaneous),None,Severe hepatic impairement,Category B3,Use with caution
Amisulpride,Antipsychotic,"Neuroactive ligand-receptor interaction, Dopaminergic synapse",DRD2,dopamine receptor antagonist,,,8.55,369.487,1.2851,6,2,7,101.73,1,9.47,0.03,0.09462,0.2622,22.02,,,,0,-11.83258764,0,0,Inactive,0,-41.85628561,0,0,Inactive,Inactive,0,3.042740981,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,2.918712589,,,,,,0,-1.444791098,,,,,,,Plasma protein binding ranges from 25% to 30% in the concentration range from 37 to 1850 ng/mL. Amisulpride distributes into erythrocytes,Approximately 12 hours,48%,None,Hypersensitivity,Category C,Not recommended 
Agomelatine,Antidepressant,"Neuroactive ligand-receptor interaction, Circadian entrainment, Serotonergic synapse","HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B","melatonin receptor agonist, serotonin receptor antagonist",,,10.22,243.306,2.527,2,1,4,38.33,0,42.24,-0.03,,0.1484,14.2,,,,0,-3.138230543,0,0,Inactive,0,-2.555753991,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-3.976563136,0,0,Inactive,Inactive,0,0.098774856,,,,,,0,-6.490698419,,,,,,,> 95%,<2 hours,< 5%,NA,NA,Category B1,Not recommended
Nitisinone,Antityrosinemia,"Ubiquinone and other terpenoid-quinone biosynthesis, Tyrosine metabolism, Phenylalanine metabolism",,hydroxyphenylpyruvate dioxygenase inhibitor,,,,329.23,2.7346,5,0,3,94.35,0,,-0.1,,0.2981,24.42,,,,39.81071706,-131.7900216,39.8107,59.6712,Inconclusive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-0.233227572,,,,,,0,-18.59799257,,,,,,,,~54 hours,90%,NA,NA,Category B3,Not recommended
Etoricoxib,NSAIDs,Arachidonic acid metabolism,PTGS2,cyclooxygenase inhibitor,,,6.1,358.85,4.17592,4,0,3,59.92,0,12.43,0.32,0.1588,0.06952,22.4,,,,0.707945784,-52.54959883,0.7079,40.5712,Inconclusive,0,1.937852938,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.121620134,0,0,Inactive,Inactive,0,-1.052400261,,,,,,0,-20.24740092,,,,,,,92%,26 hours,99%,NA,NA,Category C,Not recommended
Moclobemide,Antidepressant,"Serotonergic synapse, Dopaminergic synapse, Tryptophan metabolism, Phenylalanine metabolism, Tyrosine metabolism","MAOA, MAOB",monoamine oxidase inhibitor,,,,268.744,1.402,3,1,4,41.57,0,-1.36,0.01,0.3217,0.1695,13.94,,,,0,-75.97169548,0,0,Inactive,0,10.38585445,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.927365198,0,0,Inactive,Inactive,0,-1.360573233,,,,,,0,-17.76346825,,,,,,,"Approximately 50% (primarily to albumin) [L1350]
",1.50 hours,75%,NA,NA,Category B3,Use with caution 
Safinamide,Antiparkinsonian,"Serotonergic synapse, Dopaminergic synapse",MAOB,"dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor",,,,302.349,2.3681,3,2,7,64.35,1,,0.16,0.3615,0.04637,12.51,,,,0,0,0,0,Inactive,0,-44.11683162,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-7.405527314,0,0,Inactive,Inactive,0,-5.142339843,,,,,,0,-6.931474965,,,,,,,88–90%,21.67 hours,0.95,Amitriptyline; amoxapine; amphetamine polistirex; clomipramine; cyclobenzaprine; cyproheptadine; desipramine; desvenlafaxine; deutetrabenazine; dexmethylphenidate; dextroamphetamine; dextromethorphan; diethylpropion; doxepin; duloxetine; fentanyl; fentanyl intranasal; fentanyl transdermal; fentanyl transmucosal; imipramine; isocarboxazid; levomilnacipran; linezolid; lisdexamfetamine; maprotiline; meperidine; methadone; methamphetamine; methylphenidate; milnacipran; morphine; nefazodone; nortriptyline; ozanimod; phendimetrazine; phenelzine; protriptyline; rasagiline; selegiline; selegiline transdermal; solriamfetol; St John's Wort; tapentadol; tramadol; tranylcypromine; trazodone; trimipramine; venlafaxine,"Swelling of lungs, oral mucosa; heoatic impairment",Category B3,Not recommended
Tasimelteon,Hypnotic,"Neuroactive ligand-receptor interaction, Circadian entrainment","MTNR1A, MTNR1B",melatonin receptor agonist,,,9.8,245.322,2.2512,2,1,4,38.33,2,28.66,-0.2,,0.1536,7.34,,,,0,-20.26376557,0,0,Inactive,0,-26.63688273,0,0,Inactive,Inactive,0,-74.42759341,0,0,Inactive,0,-8.454367117,0,0,Inactive,Inactive,0,-3.831770284,,,,,,0,-8.482150736,,,,,,,"At therapeutic concentrations, tasimelteon is about 90% bound to proteins.",0.75 hours,,None,None,NA,Not recommended
Voxelotor,Anti-anemic,NA,,hemoglobin modulator,,,5.09,337.379,3.6231,6,1,6,77.24,0,4.85,-0.09,,0.1638,16.72,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The protein binding of voxeletor is 99.8%, according to in vitro studies.[L10397]","The plasma elimination half-life of voxelotor in sickle cell disease patients is about 35.5 hours, according to the FDA label.[L10397] The mean half-life in the red blood cell is 60 days. The average plasma half-life of voxelotor was 50 hours in patients with sickle cell disease, compared with 61–85 hours in healthy patients, in one clinical study.[A188126]",,lonafarnib,Hypersensitivity,NA,Not recommended
Istradefylline,Antiparkinsonian,Neuroactive ligand-receptor interaction,"ADORA1, ADORA2A, ADORA2B, ADORA3",adenosine receptor antagonist,,,,384.436,2.1241,8,0,6,80.28,0,-0.25,0.09,,0.1372,5.647,,,,0.707945784,-73.33593341,0.7079,49.827,Inconclusive,0,-2.996001756,0,0,Inactive,Inactive,0,1.789245937,0,0,Inactive,0,-1.832820499,0,0,Inactive,Inactive,0,5.210021728,,,,,,0,-18.97251207,,,,,,,"Istradefylline is approximately 98% protein bound in plasma,[A184064] mostly to serum albumin and alpha-1-acid glycoprotein.[L8225]","The terminal elimination half life of istradefylline was 64-69 hours.[A184064,A184067]",,None,None,NA,Use with caution
Amifampridine,Autoimmune disease treatment,NA,,potassium channel blocker,,,,109.132,0.246,3,2,0,64.93,0,5.4,-0.16,,0.1603,35.62,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,There is no human data on serum protein binding of amifampridine [A33863].,The plasma elimination half-life is approximately 2.5 hours for amifampridine and 4 hours for 3-N-acetylamifampridine [F272].,93-100%,None,Hypersensitivity; seizures,Category C,Use with caution
Revefenacin,Antiasthmatic,"Neuroactive ligand-receptor interaction, Cholinergic synapse",,cholinergic receptor antagonist,,,9.75,597.76,4.836,6,2,10,108.21,0,,0,,,7.44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The protein binding of revefenacin and its active metabolite is of 71% and 42% respectively.[FDA label],The apparent terminal half-life of a dose of 350 mcg of revefenacin was 22.3-70 hours.[A40025],,None,Hypersensitivity,NA,Use with caution
Tezacaftor,CFTR modulator,ABC transporters,,CFTR channel agonist,,,,520.504,3.3953,7,4,8,113.18,1,-1.16,-0.07,,0.1873,3.48,,,,,,,,,,,,,,,,,,,,,,,,,,0,6.212447154,,,,,,0,-8.555862058,,,,,,,"Tezacaftor is approximately 99% bound to plasma proteins, mainly albumin.[L6814]","The apparent half-life of tezacaftor is approximately 57.2 hours.[A179665,L6829]",,lonafarnib,None,Category B3,Use with caution
Lemborexant,Hypnotic,Neuroactive ligand-receptor interaction,"HCRTR1, HCRTR2",orexin receptor antagonist,,,8.52,410.424,3.74204,5,1,6,77,2,15.02,-0.18,,,24.6,,,,0,0,,,,0,-14.16892565,,,,,,,,,,,,,,,,0,-10.77543886,,,,,,0,-9.194696294,,,,,,,"Lemborexant is approximately 94% protein-bound _in vitro_, though the specific proteins to which it binds in plasma have not been elucidated.[L10863]","The half-life for lemborexant at doses of 5mg and 10mg is 17 and 19 hours, respectively.[L10863]",,None,Narcolepsy,Category B3,Not recommended
Riluzole,Nerve cells protectant,"Neuroactive ligand-receptor interaction, Glutamatergic synapse, Dopaminergic synapse","KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",glutamate inhibitor,,,,234.202,2.7771,4,1,1,48.14,0,4.91,-0.15,,0.1438,7.161,,,,0,13.72442103,0,0,Inactive,8.912509381,-51.37292463,0,0,Inactive,Inactive,0,-19.04576936,0,0,Inactive,0,-130.1703106,0,0,Inactive,Inactive,0,-3.60044197,,,,,,0,0.963558068,,,,,,,"96% bound to plasma proteins, mainly to albumin and lipoprotein over the clinical concentration range.",The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.,64%,None,Hypersensitivity,Category B3,Not recommended
Tamsulosin,Antidysuria,"cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D",adrenergic receptor antagonist,,,,408.52,2.3409,6,2,11,99.88,1,,-0.07,,0.1193,22.04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tamsulosin is 94%-99% protein bound, mostly to alpha-1-acid glycoprotein.[Label]",6.80 hours,99%,Ombitasvir/paritaprevir/ritonavir & dasabuvir,Hypersensitivity,Category B2,NA
Relugolix,"Antineoplastic, Anti-endometriosis","Neuroactive ligand-receptor interaction, GnRH signaling pathway",,gonadotropin releasing factor hormone receptor antagonist,,,,623.642,3.7505,11,2,9,132.61,0,,-0.04,,,3.22,,,,0,-5.77358573,,,,0,-37.80712732,,,,,,,,,,,,,,,,0,12.98535768,,,,,,0,-3.768845717,,,,,,,"Relugolix is 68-71% protein-bound in plasma, primarily to albumin and, to a lesser extent, α1-acid glycoprotein.[L27991]","The average effective half-life of relugolix is 25 hours, while the average terminal elimination half-life is 60.8 hours.[L27991]",0.12,None,None,NA,No sufficient information is available
Paritaprevir,Antiviral,Protein biosynthesis,,HCV inhibitor,,,,765.893,3.63692,10,3,7,189.65,5,0.28,-0.17,,0.151,14.05,,,,,,,,,,,,,,,,,,,,,,,,,,0,-5.94618196,,,,,,0,-18.50535767,,,,,,,97 to 98.6% bound to human plasma proteins [FDA Label].,8.71 hours,,NA,NA,NA,Not recommended
Venetoclax,Antineoplastic,Apoptosis,BCL2,BCL inhibitor,,,11,868.457,8.6599,11,3,13,172.03,0,,-0.29,,0.1129,21.72,,,,0,-15.92084643,,,,0,6.775515142,,,,,,,,,,,,,,,,0,12.36723935,,,,,,2.238721139,-111.5573818,,,,,,,Venetoclax is highly bound to human plasma protein with unbound fraction in plasma <0.01 across a concentration range of 1-30 µM (0.87-26 µg/mL). The mean blood-to-plasma ratio was 0.57 [FDA label].,"The half-life of venetoclax is reported to be 19-26 hours, after administration of a single 50-mg dose [A40022], [FDA label].",,"Atazanavir
Clarithromycin
Cobicistat
Conivaptan
Darunavir
Fosamprenavir
Grapefruit
Idelalisib
Imatinib
Indinavir
Isoniazid
Itraconazole
Ketoconazole
Lopinavir
Nefazodone
Nelfinavir
Nicardipine
Posaconazole
Ritonavir
Saquinavir
Tipranavir
Voriconazole
",Strong CYP3A inhibitors at initiation and during ramp-up phase,Category C,Not recommended
Osilodrostat,Antihypertensive,"Steroid hormone biosynthesis, Aldosterone synthesis and secretion",,cytochrome P450 inhibitor,,,8.6,227.242,2.42948,3,0,1,41.61,1,,-0.11,,,-5.55,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Both osilodrostat and its M34.5 metabolite are minimally protein-bound in plasma at less than 40%.[L12123,L12132] The extent of protein-binding is independent of drug concentration.[L12132] The specific plasma proteins to which osilodrostat binds have not been elucidated.","The elimination half-life of osilodrostat is approximately 4 hours.[L12123,A191850]",,Lefamulin,None,NA,Not recommended
Uridine triacetate,"Antidote (5-fluorouracil, capecitabine)",NA,,,,,,370.314,-1.1395,10,1,5,142.99,4,-22.84,-0.02,,0.05866,6.896,,,,0,-151.4011888,0,0,Inactive,0,-6.166535387,0,0,Inactive,Inactive,0,-23.31442524,0,0,Inactive,0,-0.194355029,0,0,Inactive,Inactive,0,2.009423624,,,,,,0,-40.73074348,,,,,,,,2 to 2.5 hours,,NA,NA,NA,Use with caution
Epinastine,Antiallergic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",HRH1,histamine receptor antagonist,,,,249.317,2.4668,3,1,0,41.62,1,-3.27,-0.08,,-0.03911,-4.851,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,64%,12 hours,0.4,NA,Hypersensitivity; contact lens related irritation,Category C,Use with caution
Varenicline,Smoking cessation adjunct,"Neuroactive ligand-receptor interaction, Cholinergic synapse","CHRNA3, CHRNA4, CHRNA6, CHRNA7",acetylcholine receptor agonist,,,,211.268,1.8039,3,1,0,37.81,2,,-0.17,,,22.78,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Less than 20%.,The elimination half-life of varenicline is approximately 24 hours,87%,None,Hypersensitivity,Category B3,Not recommended
RANOLAZINE,Vasodilator,NA,"SCN10A, SCN9A",sodium channel blocker,,,,427.545,2.30804,6,2,9,74.27,1,,,1.095,0.1142,,,,,39.81071706,-8.402266838,39.8107,43.5234,Inconclusive,0,2.646338673,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-1.24390448,,,,,,0,-28.54426624,,,,,,,Approximately 62% of the administered dose of ranolazine is bound to plasma proteins. Ranolazine appears to have a higher binding affinity for alpha-1 acid glycoprotein,1.80 hours,42.50%,"Ceritinib
Cobicistat
Darunavir
Efavirenz
Eliglustat
Itraconazole
Ketoconazole
Lefamulin
Ribociclib
","Hepatic cirrhosis, including Child-Pugh class A (mild), B (moderate), and C (severe)",Category C,Not recommended
DOMPERIDONE,"Anti-emetic, Prokinetic","Neuroactive ligand-receptor interaction, Dopaminergic synapse","DRD2, DRD3",dopamine receptor antagonist,,,,425.92,3.3532,5,2,5,78.82,0,4.8,-0.11,0.39,0.1608,7.05,,,,11.22018454,-39.77118128,11.2202,59.4962,Inconclusive,0,-6.119265208,0,0,Inactive,Inactive,39.81071706,-14.0227329,39.8107,48.0964,Inconclusive,39.81071706,-9.588627326,39.8107,31.8879,Inconclusive,Cytotoxic,0,16.13006403,,,,,,0,-32.77258697,,,,,,,91%-93%,7.50 hours,15%,NA,NA,Category B2,Not recommended
PILOCARPINE NITRATE,Miotic,"Neuroactive ligand-receptor interaction, Cholinergic synapse, Salivary secretion","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",acetylcholine receptor agonist,,,6.97,271.273,0.8141,6,1,3,107.49,2,,,,0.1136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.76 hours,,None,"Uncontrolled asthma, anterior eye inflammation, any time miosis in undesirable",Category B3,Use with caution
TRIMETHOBENZAMIDE HYDROCHLORIDE,Anti-emetic,NA,DRD2,histamine receptor antagonist,,,,424.925,3.0046,6,1,10,69.26,0,,,,0.1981,,,,,0,-3.977884476,0,0,Inactive,0,3.390053047,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.168830665,0,0,Inactive,Inactive,0,11.68802218,,,,,,0,-31.32842639,,,,,,,,The mean elimination half-life of trimethobenzamide is 7 to 9 hours.,80%,None,Hypersensitivity,NA,Not recommended
BENZOIC ACID,"Antifungal, Antiseptic",NA,"DAO, HRSP12, PRDX5, RAB9A",food preservative,,,,122.123,1.3848,1,1,1,37.3,0,33.07,-0.19,,,7.99,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NA,NA,NA,NA
UREA,"Diuretic, Emollient, Keratolytic",NA,"ARG1, CA2, CTNNB1","hydroxy radical formation stimulant
",,,,60.056,-0.9762,1,2,0,69.11,0,19.36,-0.03,,0.04168,18.24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,None,Hypersensitivity; Viral skin disease,NA,NA
MICONAZOLE NITRATE,Antifungal,Steroid biosynthesis,"TRPM2, TRPV5",bacterial cell wall synthesis inhibitor,,,,479.147,6.1071,5,1,6,90.42,1,,-0.27,-0.1193,0.003347,14.26,,,,31.6227766,-16.23344465,,,,0,-28.58427325,,,,,,,,,,,,,,,,0,3.535249746,,,,,,12.58925412,-75.55954881,,,,,,,,19.75 hours,25%,NA,Hypersensitivity; milk protein allergy,Category A,Use with caution
TIOPRONIN,Antidote (mercury),NA,,"chelating agent, reducing agent",,,,163.198,-0.4945,3,3,3,66.4,1,,0.15,,0.1099,24.6,,,,0,-71.84311816,0,0,Inactive,0,-20.40846769,0,0,Inactive,Inactive,0,0.985622581,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,1.195151158,,,,,,0,-14.09262405,,,,,,,Tiopronin undergoes extensive protein binding in plasma. It is thought that this occurs through the formation of a disulphide bridge to the free thiol group of albumin.,55 hours,63%,None,Hypersensitivity,NA,Not recommended
MIANSERIN HYDROCHLORIDE,Antidepressant,Neuroactive ligand-receptor interaction,"ADRA1A, ADRA1B, ADRA1D, HRH1, HRH2, HTR2A, HTR2B, HTR2C, HTR6, HTR7",serotonin receptor antagonist,,,8.12,300.833,3.5057,2,0,0,6.48,1,,,,0.2217,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,90%,9.60 hours,22%,NA,NA,Category B2,Not recommended
BETAHISTINE HYDROCHLORIDE,"Antivertigo, Vasodilator","Calcium signaling pathway, Neuroactive ligand-receptor interaction","HRH1, HRH3","histamine receptor agonist, histamine receptor antagonist",,,,209.12,1.6871,2,1,3,24.92,0,,,,0.1802,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,<5%,"The half-life of betahistine is 3-4 hours.[A220438,A220563,L16388]",,NA,NA,Category B3,Not recommended
BIFONAZOLE,Antifungal,Steroid biosynthesis,,sterol demethylase inhibitor,,,,310.4,5.1878,2,0,4,17.82,1,70.75,-0.11,-0.0446,,-1.13,,,,31.6227766,-23.28488786,31.6228,80.4844,Inconclusive,39.81071706,-10.76359729,39.8107,38.2072,Inconclusive,Cytotoxic,39.81071706,-31.39313483,39.8107,107.675,Inconclusive,0,-10.01068622,0,0,Inactive,Inactive,0,8.893974694,,,,10,36.432,12.58925412,-76.81131184,,,,,14.125375,24.488,,1-2 hours,,NA,NA,Category B3,NA
ENOXACIN,Antibacterial,DNA synthesis/replication,TOP2A,topoisomerase inhibitor,,,,320.324,0.6633,6,2,3,87.46,0,-14.27,-0.12,1.182,,7.669,,,,0,-42.60789196,0,0,Inactive,0,-11.77321733,0,0,Inactive,Inactive,0,-97.27821453,0,0,Inactive,0,2.67367584,0,0,Inactive,Inactive,0,-0.35800246,,,,,,0,-32.15012181,,,,,,,,5.10 hours,87%,NA,NA,Category B3,Not recommended
Rilpivirine,Anti-HIV,NA,"NR1I2, SCN10A",non-nucleoside reverse transcriptase inhibitor,,,,366.428,4.9891,6,2,5,97.42,0,82.1,1.73,,0.1167,-36.34,,,,22.38721139,-49.40789163,22.3872,115.464,Active,28.18382931,-35.58664217,35.4813,42.7423,Inconclusive,Cytotoxic,39.81071706,-70.035117,39.8107,106.141,Inconclusive,15.84893192,-44.46915358,15.8489,42.0715,Inconclusive,Cytotoxic,0,-1.512509932,,,,,,8.912509381,-80.52372913,,,,,,,"Rilpivirine is highly protein-bound thus, >99% of its dose can be bound to plasma protein in a concentration-dependent manner.[A31331] The most important plasma binding proteins is albumin.[FDA label]","Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]",,Carbamazepine; dexamethasone; dexlansoprazole; efavirenz;elvitegravir/cobicistat/emtricitabine/tenofovir DF; eslicarbazepine acetate; esomeprazole; etravirine; fosphenytoin; lansoprazole; nevirapine; omeprazole; oxcarbazepine; pantoprazole; phenobarbital; phenytoin; rabeprazole; rifampin; rifapentine; St John's Wort,Hypersensitivity,Category B1,Not recommended
Cabergoline,"Antiparkinsonian, Antidyskinetic","Neuroactive ligand-receptor interaction, Dopaminergic synapse, Prolactin signaling pathway","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7",dopamine receptor agonist,,,9.2,451.615,3.1939,4,2,8,71.68,3,,0.2,,,15.57,,,,19.95262315,-98.1251517,19.9526,97.926,Inconclusive,0,2.204313515,0,0,Inactive,Inactive,35.48133892,-0.34513027,35.4813,47.3171,Inconclusive,0,0.152899509,0,0,Inactive,Inactive,12.58925412,68.72586133,,,,,,0,-33.75430762,,,,,,,Moderately bound (40% to 42%) to human plasma proteins in a concentration-independent manner.,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,65%,"almotriptan
eletriptan
frovatriptan
glyceryl trinitrate pr
naratriptan
nitroglycerin IV
nitroglycerin sublingual
nitroglycerin topical
nitroglycerin transdermal
nitroglycerin translingual
rizatriptan
sumatriptan
sumatriptan intranasal
zolmitriptan","Uncontrolled hypertension
Hypersensitivity to ergot derivatives
Severe hepatic disease",Category B1,Not recommended
Acrivastine,Antiallergic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",HRH1,histamine receptor antagonist,,,,348.446,4.01532,3,1,6,53.43,0,28.58,0.05,,0.1912,11.52,,,,39.81071706,-18.66364175,39.8107,30.2251,Inconclusive,0,3.466940646,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,3.21311899,0,0,Inactive,Inactive,0,-0.686657643,,,,,,0,-32.0431464,,,,,,,Acrivastine binding to human plasma proteins was 50 ± 2.0%.,The mean terminal half-life for acrivastine was 1.9 ± 0.3 hours following single oral doses and increased to 3.5 ± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 ± 1.4 hours.,18%,Dihydroergotamine; dihydroergotamine inhaled; dihydroergotamine intranasal; ergoloid mesylates; ergonovine; ergotamine; isocarboxazid; linezolid; methylergonovine; phenelzine; procarbazine; rasagiline; selegiline; selegiline transdermal; tranylcypromine,Hypersensitivity; severe hypertention,NA,Use with caution
Elvitegravir,Anti-HIV,NA,,HIV integrase inhibitor,,,,447.89,4.281,5,2,7,88.76,1,7.47,0.46,,0.1404,10.31,,,,0.001122019,-356.1835003,0,0,Inactive,0,3.679002689,0,0,Inactive,Inactive,12.58925412,-222.6469686,12.5893,80.6309,Active,0,0,0,0,Inactive,Inactive,0,-1.420278371,,,,,,10,-80.60074756,,,,,,,Elvitegravir is 98–99% bound to human plasma proteins,The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.,,NA,NA,Category B2,Not recommended
Dasabuvir,Antiviral,NA,,HCV inhibitor,,,,493.585,4.0236,6,2,5,110.26,0,-10.02,0.55,0.184,0.3029,17.1,,,,5.011872336,-79.47204571,5.0119,32.765,Inconclusive,0,-3.990996553,0,0,Inactive,Inactive,39.81071706,-109.4435869,39.8107,63.7795,Inconclusive,0,0.595987514,0,0,Inactive,Inactive,12.58925412,39.48904639,,,,12.589254,48.664,3.981071706,-41.59730306,,,,,14.125375,42.532,Dasabuvir is greater than 99.5% bound to human plasma proteins [FDA Label].,5.70 hours,The absolute bioavailability of Dasabuvir is 70%.,NA,NA,NA,Use with caution
Silodosin,Antidysuria,"cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D",adrenergic receptor antagonist,,,10.44,495.542,3.0711,6,3,13,97.05,1,-9.07,-0.03,0.8702,0.3783,18,,,,39.81071706,-10.39907817,39.8107,47.6829,Inconclusive,0,-3.945999149,0,0,Inactive,Inactive,0,-2.210205697,0,0,Inactive,0,-37.71000725,0,0,Inactive,Inactive,0,-2.973387895,,,,,,0,-19.97735486,,,,,,,97% bound to protein ,3.60 hours,32%,"itraconazole
ombitasvir/paritaprevir/ritonavir & dasabuvir","Hypersensitivity
Severe renal impairment (CrCl <30 mL/min)
Severe hepatic impairment (Child-Pugh Score >10)",Category B3,Not recommended
Lumacaftor,CFTR corrector,"ABC transporters, Gastric acid secretion, Pancreatic secretion, Bile secretion",CFTR,CFTR channel agonist,,,6.46,452.413,4.74702,5,2,5,97.75,0,37.26,0.02,,0.04797,2.625,,,,3.16227766,-55.89001864,3.1623,43.2008,Inconclusive,0,0.1680592,0,0,Inactive,Inactive,0,-51.75491424,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,6.258826113,,,,,,0,-16.9324573,,,,,,,"Lumacaftor is extensively protein bound in the plasma (99%), and binds primarily to albumin.[FDA Label]",The half-life of lumacaftor is approximately 26 hours.[FDA Label],,Bosentan; carbamazepine; cariprazine; cobimetinib; dabrafenib; dexamethasone; doravirine; efavirenz; elbasvir/grazoprevir; enzalutamide; eslicarbazepine acetate; etravirine; fosphenytoin; fostemsavir; isavuconazonium sulfate; lonafarnib; lorlatinib; mitotane; nafcillin; nevirapine; oxcarbazepine; pentobarbital; phenobarbital; phenytoin; primidone; rifabutin; rifampin; rifapentine; St John's Wort,None,Category B3,Not recommended
Stiripentol,Anticonvulsant,NA,GABRA3,GABA uptake inhibitor,,,,234.295,2.8355,3,1,2,38.69,1,2.28,0.04,0.1907,,23.97,,,,39.81071706,-16.71890475,39.8107,57.344,Inconclusive,0,-13.23716458,0,0,Inactive,Inactive,0,2.4004399,0,0,Inactive,0,1.623265504,0,0,Inactive,Inactive,0,-1.94764978,,,,,,0,-30.55666365,,,,,,,Stiripentol binds extensively to circulating plasma proteins (about 99%) [L880].,"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].",,Finerenone; idelalisib; isavuconazonium sulfate; lonafarnib; voclosporin,NA,Category B3,Not recommended
Pretomanid,Antibacterial (tuberculostatic),NA,FASN,nitric oxide donor,,,,359.26,2.6677,7,0,5,88.65,1,-0.06,0.08,,,-11.24,,,,0,-5.306319602,,,,0,-7.176977968,,,,,,,,,,,,,,,,0,-3.708231357,,,,,,0,-20.22684312,,,,,,,The plasma protein binding of pretomanid is about 86.4%.[L8048],The elimination half-life was determined to be 16.9-17.4 hours in a pharmacokinetic study of healthy subjects.[L8048] An FDA briefing document reports a half-life of 18 hours.[L8057],,None,None,NA,Use with caution
Rufinamide,Anticonvulsant,Dopaminergic synapse,"GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",voltage-gated sodium channel blocker,,,,238.197,0.7035,4,1,3,73.8,0,-10.47,-0.04,0.3352,0.1638,-8.338,,,,0,-95.86933835,0,0,Inactive,0,0.252166013,0,0,Inactive,Inactive,0,-18.7064035,0,0,Inactive,0,-5.001427267,0,0,Inactive,Inactive,0,0.082196392,,,,,,0,-14.46471419,,,,,,,26.3% - 34.8% with 90% binding to albumin (27%).,"Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.",85%,None,Hypersensitivity; Familial short QT syndrome,Category B3,Not recommended
(+)-Camphor,"Analgesic, Anti-inflammatory, Antipruritic",NA,,,,,,152.237,2.4017,1,0,0,17.07,2,4.08,-0.14,,,28.93,,,,0,-14.17479775,0,0,Inactive,0,4.789257107,0,0,Inactive,Inactive,0,-11.39899869,0,0,Inactive,0,-18.47225354,0,0,Inactive,Inactive,0,-3.329756105,,,,,,0,-11.52310881,,,,,,,,,,Artemether/lumefantrine; cariprazine; cobimetinib; dienogest/estradiol valerate; doravirine; elbasvir/grazoprevir; elvitegravir/cobicistat/emtricitabine/tenofovir DF; lonafarnib; lumacaftor/ivacaftor; lumefantrine; lurasidone; naloxegol; ombitasvir/paritaprevir/ritonavir & dasabuvir; oxcarbazepine; panobinostat; praziquantel; regorafenib; rilpivirine; roflumilast; vandetanib,Hypersensitivity,NA,NA
Parecoxib,NSAIDs,Arachidonic acid metabolism,LTF,cyclooxygenase inhibitor,,,8.3,370.43,3.53192,5,1,5,89.27,0,5.85,-0.11,,0.03281,24.92,,,,0,-16.32548116,0,0,Inactive,0,1.429513781,0,0,Inactive,Inactive,0,-0.602538606,0,0,Inactive,0,2.12911487,0,0,Inactive,Inactive,0,-0.735643891,,,,,,0,-16.28390815,,,,,,,98%,22 minutes (parecoxib)| 8 hours (valdecoxib),,NA,NA,Category C,Not recommended
Saxagliptin,Antidiabetic,Protein digestion and absorption,DPP4,dipeptidyl peptidase inhibitor,,,9.22,315.417,1.15798,4,2,2,90.35,8,-4.62,0,,,2.652,,,,0,-12.63407141,0,0,Inactive,0,-2.820517765,0,0,Inactive,Inactive,0,8.056316388,0,0,Inactive,0,-0.718675517,0,0,Inactive,Inactive,0,8.086467056,,,,,,0,5.661891902,,,,,,,The in vitro protein binding of saxagliptin and its active metabolite in human serum is negligible (<10%).,7.50 hours,"Bioavailability, 2.5 - 50 mg dose = 67%",None,Hypersensitivity,Category B3,Use with caution
Bosutinib,Antineoplastic,ErbB signaling pathway,"ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK","Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor",,,10.54,530.456,5.19038,8,1,9,82.88,0,18.71,-0.33,-0.3065,0.09732,-1.12,,,,3.16227766,-96.63655942,,,,14.12537545,-83.00742285,,,,,,,,,,,,,,,,0,-8.977021767,,,,,,7.943282347,-117.5169597,,,,,,,94% bound to human plasma proteins in vitro. 96% bound to human plasma proteins in healthy subjects ex vivo. Extent of protein binding is not concentration-dependent. ,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",,lefamulin,Hypersensitivity,NA,Not recommended
Selexipag,"Antihypertensive, Vasodilator","Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation",PTGIR,"IP1 prostacyclin receptor agonist, platelet aggregation inhibitor",,,,496.633,3.898,7,1,12,101.49,0,-2.21,-0.08,,0.0592,10.87,,,,39.81071706,-45.63190366,39.8107,60.2787,Inconclusive,0,-1.869665555,0,0,Inactive,Inactive,0,-7.759739299,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,7.526524546,,,,,,0,-18.41448732,,,,,,,"Both selexipag and its active metabolite are highly protein bound, approximately 99%.",Selexipag's terminal half life is 0.8-2.5 hours. The active metabolite's terminal half life is 6.2-13.5 hours.,,Gemfibrozil,Concomitant use of strong CYP2C8 inhibitors,Category B1,Not recommended
Cinacalcet,"Antihypercalcemia, Antihyperparathyroidism","NOD-like receptor signaling pathway, Parathyroid hormone synthesis, secretion and action",CASR,calcium channel activator,,,7.7,357.419,6.142,1,1,6,12.03,1,,-0.38,,-0.07555,18.38,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Approximately 93 to 97% bound to plasma proteins.,19.90 hours,20%,Eliglustat; etelcalcetide,Hyoersensitivity; decreased serum calcium,Category B3,Not recommended
GUAIACOL,"Analgesic, Disinfectant",NA,CA2,,,,,124.139,1.4008,2,1,1,29.46,0,,,0.2494,,,,,,0,-15.06583958,0,0,Inactive,0,-59.48547569,0,0,Inactive,Inactive,0,3.329916268,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,6.257298955,,,,,,0,-13.15651465,,,,,,,,,,NA,NA,NA,NA
ETHYLENEDIAMINE TETRACETATE TETRA-ETHANOLAMINE,NA,NA,,,,,,536.58,-6.3216,14,12,15,340.68,0,-2.85,-0.05,,,2.523,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The half life of edetate calcium disodium is 20-60 minutes.[L12774],,NA,NA,NA,NA
ALENDRONATE SODIUM,"Osteoporosis agent, Antiresorptive",Terpenoid backbone biosynthesis,"ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS",bone resorption inhibitor,,,,326.131,-6.7433,4,6,5,255.81,0,,-0.19,,,4.25,,,,0,-6.120428415,0,0,Inactive,0,0.843931252,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,3.186374568,,,,,,0,-1.654900642,,,,,,,,3.10 hours,1%,"Human parathyroid hormone, recombinant",Hypersensitivity; Hypocalcemia,Category B3,Not recommended
RIZATRIPTAN BENZOATE,"Antimigraine, Vasoconstrictor","Neuroactive ligand-receptor interaction, Serotonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",serotonin receptor agonist,,,6.9,391.475,3.2966,5,2,6,87.04,0,-3.9,0.07,0.7991,,-3.916,,,,25.11886432,-12.96989582,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.298560362,0,0,Inactive,Inactive,0,-0.084913704,,,,,,0,-22.60824124,,,,,,,14%,2.20 hours,45%,"almotriptan
cabergoline
dihydroergotamine
dihydroergotamine intranasal
eletriptan
ergoloid mesylates
ergotamine
frovatriptan
methylergonovine
naratriptan
procarbazine
sumatriptan
sumatriptan intranasal
zolmitriptan","Hypersensitivity
Coronary artery vasospasm
History of stroke or transient ischemic attack
Ischemic bowel
Peripheral vascular disease
Basilar or hemiplegic migraine",Category B1,Use with caution
METAXALONE,Skeletal muscle relaxant,NA,,,,,,221.256,1.79064,3,1,3,47.56,1,-6.36,0.12,,0.2292,4.879,,,,0,-10.21904745,0,0,Inactive,0,-28.56619021,0,0,Inactive,Inactive,0,0.51930652,0,0,Inactive,0,-24.91748909,0,0,Inactive,Inactive,0,-2.741001034,,,,,,0,-7.591595644,,,,,,,,9.2 (+/- 4.8) hours,,None,Hypersensitivity; renal/hepatic impairement,Category C,Not recommended
DONEPEZIL HYDROCHLORIDE,Anti-Alzheimer's,"Glycerophospholipid metabolism, Cholinergic synapse",ACHE,acetylcholinesterase inhibitor,,,,415.961,4.7829,4,0,6,38.77,1,,-0.2,,0.173,18.24,,,,39.81071706,-22.0683885,39.8107,75.6921,Inconclusive,0,4.254292812,0,0,Inactive,Inactive,39.81071706,-11.48366028,39.8107,38.3877,Inconclusive,0,-0.971795709,0,0,Inactive,Inactive,0,-1.909780602,,,,,,0,-0.743334591,,,,,,,"96% protein-bound, with approximately 75% binding to albumin and approximately 21% binding to alpha-1-glycoprotein","The average elimination half-life of donepezil is about 70 hours according to the results of various studies and the FDA label for donepezil.[A182333,L7916]. One pharmacokinetic study determined the average terminal half-life to be 81.5±22.0 h[A182324]",99%,None,Hypersensitivity,Category B3,Not recommended
FAMPRIDINE,Multiple Sclerosis Agent,NA,,,,,,94.117,0.6638,2,1,0,38.91,0,-6.59,-0.05,0.1168,0.1111,27.93,,,,0,-151.4324653,0,0,Inactive,0,11.12891416,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-3.149196958,,,,,,0,-22.44053921,,,,,,,10 mg extended release = 1-3% protein bound,3.60 hours,Relative bioavailability of 10 mg extended-release tablets compared to aqueous oral solution = 96%,NA,Hypersensitivity; history of seizures,Category C,Not recommended
CYSTEAMINE HYDROCHLORIDE,Anti-urolithic (cysteine calculi),,"NPY2R, SST",tissue transglutaminase inhibitor,,,,113.613,0.2967,2,2,1,26.02,0,,,,0.253,,,,,0,-66.28691718,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,7.089936575,0,0,Inactive,Inactive,0,6.788145336,,,,,,0,1.701907315,,,,,,,52%,The half-life of cysteamine is about 3.7 hours.[A218941],,NA,Hypersensitivity,Category B3,Not recommended
ZOLMITRIPTAN,"Antimigraine, Vasoconstrictor","Neuroactive ligand-receptor interaction, Seratonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",serotonin receptor agonist,,,8.9,287.363,1.9229,3,2,5,57.36,1,7.85,0.24,0.4913,0.1454,25.69,,,,39.81071706,-62.03818209,39.8107,40.8308,Inconclusive,0,1.535060667,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-0.049050801,,,,,,0,-1.18744114,,,,,,,Zolmitriptan and its active N-desmethyl metabolite remain approximately 25% bound to plasma proteins over a concentration range of 10-1000 ng/mL,3.60 hours,45%,"almotriptan
bromocriptine
cabergoline
dihydroergotamine
dihydroergotamine intranasal
eletriptan
ergoloid mesylates
ergotamine
frovatriptan
methylergonovine
naratriptan
procarbazine
rizatriptan
sumatriptan
sumatriptan intranasal","Hypersensitivity
History of myocardial infarction
Ischemic or vasospastic artery disease
Peripheral vascular disease
Ischemic bowel disease",Category B3,Use with caution 
FUSIDIC ACID,Antibacterial,NA,,bacterial 30S ribosomal subunit inhibitor,,,,516.719,5.6661,5,3,5,104.06,10,6.87,0.04,,,8.77,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,97 to 99%,Approximately 5 to 6 hours in adults.,91%,NA,NA,Category C,Use with caution
MEBEVERINE HYDROCHLORIDE,"Antispasmodic, Smooth muscle relaxant","Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse",CHRM1,acetylcholine receptor antagonist,,,,466.018,5.0243,6,0,13,57.23,1,,,,0.1457,,,,,11.22018454,-48.60249735,11.2202,68.1397,Active,0,16.57627023,0,0,Inactive,Inactive,39.81071706,-21.36239117,39.8107,73.2706,Inconclusive,0,-5.529893135,0,0,Inactive,Inactive,0,4.90429728,,,,,,0,-27.33328901,,,,,,,,,,NA,NA,Category B2,Use with caution
SUMATRIPTAN,"Antimigraine, Vasoconstrictor","Neuroactive ligand-receptor interaction, Serotonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7",serotonin receptor agonist,,,,295.408,1.3212,3,2,6,65.2,0,-0.78,-0.04,,0.2609,15.35,,,,0,0,0,0,Inactive,0,3.335673098,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,11.50400309,,,,,,0,-22.99016512,,,,,,,14-21%,1.70 hours,14%,"almotriptan
bromocriptine
cabergoline
dihydroergotamine
dihydroergotamine intranasal
eletriptan
ergoloid mesylates
ergotamine
frovatriptan
methylergonovine
naratriptan
procarbazine
rizatriptan
zolmitriptan",Severe hepatic impairment; history of stroke; transient ischemic attack,Category B3,Use with caution 
FEXOFENADINE HYDROCHLORIDE,Antiallergic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",HRH1,histamine receptor antagonist,,,8,538.128,5.9323,4,3,10,81,1,,,,0.1118,,,,,6.309573445,-10.71723336,6.3096,32.3993,Inconclusive,0,8.438076289,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,9.02137978,0,0,Inactive,Inactive,0,6.428590678,,,,,,0,-3.817467539,,,,,,,60-70%,"The terminal elimination half-life is approximately 11-15 hours.[L10779,A1495]",70%,None,Hypersensitivity,Category B2,Use with caution
LOFEXIDINE  HYDROCHLORIDE,Antihypertensive,Neuroactive ligand-receptor interaction,,adrenergic receptor agonist,,,8.36,295.597,3.1842,3,1,3,33.62,1,,-0.11,0.03818,0.1853,14.75,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,55% of administered dose,The reported elimination half-life of lofexidine is 11 hours.[T55],90%,None,None,NA,Use with caution
ALFUZOSIN HYDROCHLORIDE,"Antidysuria, Antihypertensive","cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",adrenergic receptor antagonist,,,8.55,425.917,1.7725,8,2,8,111.83,1,,,,0.1086,,,,,39.81071706,-19.93802843,39.8107,68.3852,Inconclusive,15.84893192,-53.08760273,0,0,Inactive,Inactive,39.81071706,-32.49831445,39.8107,111.466,Inconclusive,0,-63.21129643,0,0,Inactive,Inactive,0,5.573321162,,,,,,0,-10.16535314,,,,,,,82-90%,4.80 hours,55%,"atazanavir
ceritinib
chloramphenicol
cisapride
clarithromycin
cobicistat
darunavir
dronedarone
elvitegravir/cobicistat/emtricitabine/tenofovir DF
fluconazole
fosamprenavir
idelalisib
indinavir
itraconazole
ketoconazole
lefamulin
lopinavir
mifepristone
nefazodone
nelfinavir
ombitasvir/paritaprevir/ritonavir & dasabuvir
posaconazole
ritonavir
saquinavir
thioridazine
tipranavir
voriconazole","Hypersensitivity
Moderate to severe liver impairment",Category B2,Not recommended
FAMCICLOVIR,Antiviral,DNA synthesis/replication,,DNA polymerase inhibitor,,,,321.337,0.541,9,1,7,122.22,0,-6.05,-0.08,0.2587,0.02613,9.899,,,,0,-4.229773263,0,0,Inactive,0,-3.23016764,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-33.0731731,0,0,Inactive,Inactive,0,4.567967581,,,,,,0,-23.13213711,,,,,,,20-25%,10 hours,77%,Varicella virus vaccine live; zoster vaccine live,Hypersensitivity,Category B1,Use with caution
NEFOPAM,Analgesic,NA,,cyclooxygenase inhibitor,,,,253.345,3.238,2,0,1,12.47,1,-6.62,-0.05,,,29.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5 hours,36%,NA,NA,NA,Recommended
ALMOTRIPTAN,Antimigraine,"Neuroactive ligand-receptor interaction, Seratonergic synapse","HTR1B, HTR1D",serotonin receptor agonist,,,8,335.473,2.1976,3,1,6,56.41,0,,,,0.03586,,,,,0,2.282377859,0,0,Inactive,0,2.472437747,0,0,Inactive,Inactive,0,-10.60258012,0,0,Inactive,0,2.283325508,0,0,Inactive,Inactive,0,1.421262512,,,,,,0,-16.28695685,,,,,,,35%,3.40 hours,70%,"bromocriptine
cabergoline
dihydroergotamine
dihydroergotamine intranasal
eletriptan
ergoloid mesylates
ergotamine
frovatriptan
methylergonovine
naratriptan
procarbazine
rizatriptan
sumatriptan
sumatriptan intranasal
zolmitriptan","Hypersensitivity, severe hepatic or renal impairment, migraine prophylaxis",NA,Not recommended
VALACYCLOVIR HYDROCHLORIDE,Antiviral,DNA synthesis/replication,,,,,,360.802,-0.3758,9,3,7,151.14,1,,-0.2,,0.03059,6.38,,,,39.81071706,-53.01135434,39.8107,66.7301,Inconclusive,0,0.285630528,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-0.449541765,,,,,,0,-15.30384158,,,,,,,13.5-17.9%,The plasma elimination half-life of acyclovir typically averaged 2.5 to 3.3 hours in several studies of valacyclovir in volunteers with normal renal function [FDA label].,The absolute bioavailability of acyclovir after administration of valacyclovir was measured at 54.5% ± 9.1% after the administration of a 1 gram oral dose of valacyclovir and a 350 mg intravenous (IV) acyclovir dose to 12 healthy subjects,None,Hypersensitivity,Category B3,Use with caution
GRAMICIDIN (gramicidin A shown),Antibacterial,NA,,bacterial permeability inducer,,,,1882.332,4.3723,17,21,53,548.99,14,21.89,0.19,,,17.26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NA,NA,NA,NA
EUGENOL,"Analgesic (dental), Disinfectant",NA,AR,androgen receptor antagonist,,,,164.204,2.1293,2,1,3,29.46,0,,0.02,,0.2298,14.47,,,,0,-31.5538779,0,0,Inactive,0,3.323220378,0,0,Inactive,Inactive,0,-34.51470758,0,0,Inactive,0,-4.625409364,0,0,Inactive,Inactive,0,-3.521465349,,,,,,0,-15.39638851,,,,,,,,,,NA,NA,NA,NA
ANTAZOLINE,Antiallergic,"Calcium signaling pathway, Neuroactive ligand-receptor interaction",HRH1,antihistamine,,,,265.36,2.6949,3,1,5,27.63,0,,,,0.1577,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.29 hours,,NA,NA,NA,NA
CAPSAICIN,Analgesic (topical),Neuroactive ligand-receptor interaction,"CFTR, TRPV1",TRPV agonist,,,,305.418,3.7896,3,2,9,58.56,0,1.12,-0.12,,0.1538,26.63,,,,0,-27.8973115,,,,0,-18.37713327,,,,,,,,,,,,,,,,0,-3.374946234,,,,,,0,-12.08591899,,,,,,,,"Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min [A32319]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [A32319]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [A32319].",,None,Hypersensitivity,NA,
HEXYLRESORCINOL,"Anthelmintic, Antiseptic",NA,TYR,,,,,194.274,3.2206,2,2,5,40.46,0,9.12,0.01,,0.2337,15.77,,,,0,-266.743467,0,0,Inactive,0,-114.8138944,0,0,Inactive,Inactive,0.891250938,-157.3408152,0.8913,93.7561,Active,39.81071706,-46.89155104,39.8107,90.6664,Inconclusive,Cytotoxic,0,-1.324503769,,,,,,0,-36.13365309,,,,,,,,"Readily accessible data regarding the half-life of hexylresorcinol is not available. Nevertheless, when hexylresorcinol is employed in its primary indication as a topical antiseptic or an oral anesthetic, it is generally accepted that pharmacokinetic considerations do not arise since the pharmacological action is local to the topically applied or oro-pharyngeal cavity area [L2735, F57, F58].",,NA,Hypersensitivity,Category C,No sufficient information is available
CYCLIZINE,Anti-emetic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",,histamine receptor antagonist,,,8.35,266.388,3.0234,2,0,3,6.48,0,-0.71,0.01,,0.1379,22.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,13.53 hours,,None,"Not to be used in asthma, glaucoma, emphysema, chronic pulmonary disease, shortness of breath, difficulty in breathing or difficulty in urination due to enlargement of the prostate gland",Category B3,Not recommended
PROCYCLIDINE HYDROCHLORIDE,"Antiparkinsonian, Skeletal muscle relaxant","Neuroactive ligand-receptor interaction, Cholinergic synapse",,acetylcholine receptor antagonist,,,8.34,323.908,4.3622,2,1,5,23.47,1,,,,0.2175,,,,,39.81071706,-18.35942803,10,30.4467,Inconclusive,0,-0.080055323,0,0,Inactive,Inactive,3.548133892,-71.05067187,3.5481,59.2229,Inconclusive,0,-7.828989871,0,0,Inactive,Inactive,0,22.30231787,,,,,,0,-10.54761591,,,,,,,100%,12 hours,,NA,NA,Category A,NA
MESALAMINE,Anti-inflammatory,NA,,,,7.53E+03,5.12,153.137,0.6726,3,3,1,83.55,0,-4.82,-0.12,0.3772,0.1964,7.437,,,,31.6227766,-164.1986062,31.6228,32.152,Inconclusive,0,0,0,0,Inactive,Inactive,0,-5.192578285,0,0,Inactive,0,1.672845397,0,0,Inactive,Inactive,0,0.843171377,,,,,,0,-18.29646341,,,,,,,43%,0.61 hours,,None,Hypersensitivity; breastfeeding,NA,Use with caution
GUANETHIDINE,Antihypertensive,Synaptic vesicle cycle,SLC6A2,adrenergic inhibitor,,,,198.314,0.73557,2,3,3,65.14,0,,,,0.1165,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.5 days,20%,NA,NA,Category A,NA
GEMFIBROZIL,Antihyperlipidemic,"PPAR signaling pathway, Adipocytokine signaling pathway","LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1",lipoprotein lipase activator,,,4.23,250.338,3.57324,2,1,6,46.53,0,3.12,-0.17,0.2785,0.05216,31.76,,,,0,-18.64106194,0,0,Inactive,0,10.20667815,0,0,Inactive,Inactive,0,14.91858108,0,0,Inactive,0,-0.940084123,0,0,Inactive,Inactive,0,-2.824674194,,,,,,0,-27.77773778,,,,,,,99%,Gemfibrozil has a plasma half-life of 1.5 hours.[L8525] In patients with renal failure the half life is 2.4h and in patients with liver disease the half life is 2.1h.[A185813],98%,Atorvastatin; elagolix; enzalutamide; fluvastatin; ombitasvir/paritaprevir/ritonavir & dasabuvir; pitavastatin; pravastatin; repaglinide; rosuvastatin; selexipag; simvastatin,Hypersensitivity;,Category B3,Not recommended
SULFACETAMIDE,Antibacterial,Folate biosynthesis,,PABA antagonist,,,,214.246,0.0936,4,2,2,89.26,0,-3.73,-0.23,,0.2126,13.66,,,,0,-21.97239218,0,0,Inactive,0,-36.12405438,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-79.78038325,0,0,Inactive,Inactive,0,-3.162920785,,,,,,0,-15.75799731,,,,,,,,7-12.8 hours,,NA,NA,Category C,Not recommended
BENZONATATE,Antitussive,NA,SCN5A,local anesthetic,,,,603.75,2.8346,12,1,32,121.4,0,,,,0.09156,,,,,44.66835922,-177.1939654,0,0,Inactive,28.18382931,-1.062552279,0,0,Inactive,Inactive,39.81071706,-31.74484979,39.8107,108.881,Inconclusive,0,-5.035545993,0,0,Inactive,Inactive,0,-7.958129668,,,,,,0,-10.87862823,,,,,,,,The half life of benzonatate following oral administration of 100 mg in healthy Chinese volunteers was 1.01 ± 0.41 h.[A190267],,NA,Hypersensitivity,Category C,Use with caution
DEXTROMETHORPHAN HYDROBROMIDE,Antitussive,"Neuroactive ligand-receptor interaction, Glutamatergic synapse","CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4","glutamate receptor antagonist, sigma receptor agonist",,,5.7,352.316,3.9613,2,0,1,12.47,3,,,,0.09056,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,60-70%,Dextromethorphan has a half life of 3-30 hours.[A215382],11%,Isocarboxazid; phenelzine; procarbazine; rasagiline; safinamide; selegiline; tranylcypromine,Serotonin syndrome,Category A,Not recommended
CLIDINIUM BROMIDE,Anti-ulcerative,"Neuroactive ligand-receptor interaction, Cholinergic synapse, Gastric acid secretion","CHRM1, CHRM3",acetylcholine receptor antagonist,,,9.6,432.358,-0.2915,3,1,4,46.53,3,,-0.17,,0.116,18.17,,,,0,8.375349043,0,0,Inactive,0,16.10495424,0,0,Inactive,Inactive,0,0.723171643,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,4.522916816,,,,,,0,-8.249829588,,,,,,,,,,None,"Hypersensitivity
Glaucoma
Prostatic hypertrophy
Benign bladder neck obstruction
Severe respiratory depression",NA,NA
GLUCONOLACTONE,Chelating agent,NA,LCT,,,,,178.14,-3.0132,6,4,1,107.22,4,13.48,-0.12,,,-1.322,,,,0,-29.21710069,0,0,Inactive,0,3.367739276,0,0,Inactive,Inactive,0,1.362696216,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,4.157283012,,,,,,0,-29.17980059,,,,,,,,,,NA,NA,NA,NA
METAPROTERENOL,Bronchodilator,"Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction",ADRB2,adrenergic receptor agonist,,,,211.261,1.1292,4,4,4,72.72,1,-4.16,0.18,,-0.1316,11.26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.41 hours,,NA,Hypersensitivity; Tachycardia,Category C,Use with caution
METHENAMINE,"Antibacterial, Antiseptic",NA,,bacterial DNA inhibitor,,,,140.19,-1.0198,4,0,0,12.96,4,-2.65,-0.12,0.2897,0.2305,6.189,,,,0,-77.16225557,0,0,Inactive,0,-6.87848719,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-1.354548881,0,0,Inactive,Inactive,0,1.60659242,,,,,,0,-8.194069743,,,,,,,,Elimination half-life = 3-4 hours assuming normal renal function. (1),,NA,Hypersensitivity; Severe ranal/hepatic insufficiency,Category A,Use with caution
ORPHENADRINE CITRATE,Skeletal muscle relaxant,"Calcium signaling pathway, Neuroactive ligand-receptor interaction, Glutamatergic synapse",,acetylcholine receptor antagonist,,,5.2,461.511,2.41412,6,4,11,144.6,1,,0.03,,,7.93,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,95%,13-20 hours,,NA,"Hypersensitivity; Narrow-angle glaucoma; Pyloric/duodenal obstruction, BPH, stenosing peptic ulcers, cardiospasm (mega-esophagus), myasthenia gravis, obstructive uropathy, paralytic ileus, ulcerative colitis, toxic megacolon, achalasia",Category B2,Not recommended
Uridine,NA,NA,"LSM6, TYMP",dopamine receptor agonist,,,,244.203,-2.8519,7,4,2,124.78,4,3.88,-0.22,,,31.53,,,,0,-156.6250647,,,,0,-2.34956466,,,,,,,,,,,,,,,,0,11.74001397,,,,,,0,-17.50930674,,,,,,,,,,NA,NA,NA,Use with caution
MANNITOL,"Diuretic, Antihypertensive (intracranial, intraocular), Diagnostic aid (renal function determination)",NA,,,,,,182.172,-3.5854,6,6,5,121.38,4,-29.88,0.08,,,13.85,,,,0,0,,,,0,-0.046902475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.70 hours,7%,NA,Hypersensitivity; Anuria; hypovolemia,Category B2,Use with caution
Ondansetron,Anti-emetic,Serotonergic synapse,"HTR3A, HTR3B",serotonin receptor antagonist,,0.09,10.04,293.37,3.12852,4,0,2,39.82,1,,0.43,,0.03849,21.17,,,,39.81071706,-36.62229775,39.8107,63.8372,Inconclusive,0,10.04653386,0,0,Inactive,Inactive,0,10.20955714,0,0,Inactive,0,5.856562314,0,0,Inactive,Inactive,0,-1.764642754,,,,,,0,-19.86649003,,,,,,,"The plasma protein binding associated with ondansetron was documented as approximately 73% [F3181, F3184].",3.40 hours,62%,Apomorphine; dronedarone; lefamulin; posaconazole,Hypersensitivity,Category B1,Not recommended
Inosine,Immunostimulant,NA,"PARP1, PNP",neurotrophic agent,,,,268.229,-2.2689,8,4,2,133.49,4,,,-0.08895,,,,,,0,1.986363677,0,0,Inactive,0,-4.685728235,0,0,Inactive,Inactive,0,-173.8535381,0,0,Inactive,0,-16.92537026,0,0,Inactive,Inactive,0,-4.486351467,,,,,,0,-23.27471509,,,,,,,,,,NA,NA,NA,NA
Carglumic Acid,Antihyperammonemic,NA,CPS1,carbamoyl phosphate synthase activator,,,,190.155,-1.0273,3,4,5,129.72,1,7.18,-0.08,,0.1387,-4.06,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Median values for the terminal half-life was 5.6 hours (range 4.3-9.5).,0.3,NA,NA,Category B1,Not recommended
L-Cycloserine,Antibacterial (tuberculostatic),"D-Alanine metabolism, Peptidoglycan biosynthesis",,,,2.62E+05,3.58,102.093,-1.6249,3,2,0,64.35,1,,,1.42,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,-0.32265073,,,,,,0,-23.14784954,,,,,,,,,,NA,NA,Category C,Use with caution
Galanthamine,Anti-Alzheimer's,"Glycerophospholipid metabolism, Cholinergic synapse",AChE,acetylcholinesterase inhibitor,,,7.21,287.359,1.8503,4,1,1,41.93,3,1.53,-0.14,,0.2532,9.86,,,,0,-0.449189359,0,0,Inactive,0,-14.87576942,0,0,Inactive,Inactive,0,-70.42828382,0,0,Inactive,0,7.461606537,0,0,Inactive,Inactive,0,3.274323879,,,,,,0,-23.67345502,,,,,,,18%,5.30 hours,99%,NA,NA,Category B1,Not recommended
Levetiracetam,Anticonvulsant,ECM-receptor interaction,"CACNA1B, SCN1A, SV2A",calcium channel blocker,,,6.1,170.212,-0.1273,2,1,3,63.4,1,13.42,-0.02,0.008913,0.04659,4.118,,,,0,-9.578996805,,,,0,2.194939496,,,,,,,,,,,,,,,,0,-1.14500812,,,,,,0,-15.83665762,,,,,,,<10%,8.23 hours,99%,None,Hypersensitivity,Category B3,Not recommended
Voriconazole,Antifungal,Steroid biosynthesis,"CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1",cytochrome P450 inhibitor,,,8.73,349.316,2.1769,6,1,5,76.72,2,-2.98,-0.12,0.00006668,0.166,9.578,,,,0,-20.64709217,0,0,Inactive,0,-0.252900342,0,0,Inactive,Inactive,0,-256.5160727,0,0,Inactive,0,-18.0515209,0,0,Inactive,Inactive,0,2.33931092,,,,,,0,-26.85638803,,,,,,,58%,5.60 hours,96%,Alfuzosin; carbamazepine; chloroquine; cobimetinib; conivaptan; dihydroergotamine; dihydroergotamine intranasal; efavirenz; eliglustat; ergoloid mesylates; ergonovine; ergotamine; finerenone; flibanserin; isavuconazonium sulfate; ivabradine; lefamulin; lomitapide; lonafarnib; lovastatin; lurasidone; methylergonovine; mirtazapine; naloxegol; phenobarbital; pimozide; quinidine; regorafenib; rifabutin; rifampin; ritonavir;sirolimus; St John's Wort; venetoclax; voclosporin,"HypersensitivitY; Patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption",Category B3,Not recommended
Isosorbide mononitrate,Vasodilator (coronary),NA,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",nitric oxide stimulant,,,,191.139,-1.2782,6,1,2,91.06,4,-2.1,-0.08,0.4835,0.1018,17.33,,,,0,-22.62457539,0,0,Inactive,0,1.126061146,0,0,Inactive,Inactive,0,-41.32001598,0,0,Inactive,0,-10.17061455,0,0,Inactive,Inactive,0,-3.59293739,,,,,,0,-21.11222957,,,,,,,5%,4.10 hours,93%,Avanafil; riociguat; sildenafil; tadalafil; vardenafil,Hypersensitivityl PDE-5 inhibitors,Category B2,Not recommended
Deflazacort,Anti-inflammatory,Neuroactive ligand-receptor interaction,NR3C1,glucocorticoid receptor agonist,,,,441.524,2.5632,7,1,3,102.26,8,,,0.4333,0.3895,,,,,0,3.004065231,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,3.886839808,0,0,Inactive,Inactive,0,-1.808185056,,,,,,0,-3.118318657,,,,,,,"The protein binding of the active metabolite of deflazacort is approximately 40%.[FDA label,A18759]","The half-life of deflazacort ranges from 1.1 to 1.9 h [A18725,L6703]",68%,mifepristone,Hypersensitivity ,NA,Not recommended 
Orlistat,Antiobesity,"Glycerolipid metabolism, Pancreatic secretion, Fat digestion and absorption","CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP",lipase inhibitor,,0.04,10.39,495.745,6.8819,5,1,23,81.7,4,-3.03,0.77,,0.2509,37.35,,,,0,0,0,0,Inactive,0,15.35785028,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,7.720739702,0,0,Inactive,Inactive,0,6.83501373,,,,,,12.58925412,-75.74974603,,,,,,,>99% bound to plasma proteins (lipoproteins and albumin were major binding proteins).,1 to 2 hours.,1%,None,"Pregnancy
Chronic malabsorption syndrome
Cholestasis
Hypersensitivity",Category B1,Not recommended 
Moxidectin,Antiparasitic,NA,,chloride channel antagonist,,,,639.83,5.7289,9,2,3,116.04,10,,,,0.3085,,,,,10,-32.90467245,17.7828,66.6212,Inconclusive,0,-56.35418478,0,0,Inactive,Inactive,0,-86.46158184,0,0,Inactive,0,1.261892705,0,0,Inactive,Inactive,0,24.75448351,,,,,,3.548133892,-57.39317203,,,,,,,This pharmacokinetic property in humans is unknown.[FDA label],Moxidectin reporter terminal half-life is 20.2 days.[A33398],,NA,None,NA,Use with caution 
HYDROXYZINE PAMOATE,Anxiolytic,"Calcium signaling pathway, Neuroactive ligand-receptor interaction",HRH1,antihistamine,,,,763.287,7.4473,8,5,12,151,1,-2.82,-0.13,,,29.11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The half-life of hydroxyzine is reportedly 14-25 hours, and appears to be, on average, shorter in children (~7.1 hours) than in adults (~20 hours). Elimination half-life is prolonged in the elderly, averaging approximately 29 hours, and is likely to be similarly prolonged in patients with renal or hepatic impairment",,NA,Hypersensitivity; Prolonged QT interval,Category A,Use with caution
Diazoxide,Antihypoglycemia,Insulin secretion,"ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3",potassium channel activator,,194000,3.71,230.676,1.8726,3,1,0,58.53,0,,0,0.02926,0.1379,11.11,,,,0,-17.4302112,0,0,Inactive,0,0.120028933,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-8.072316494,0,0,Inactive,Inactive,0,-2.097695373,,,,,,0,-8.958761539,,,,,,,>90%,48 hours,90%,NA,NA,Category C,Not recommended
Cefaclor,Antibacterial,Peptidoglycan biosynthesis,,bacterial cell wall synthesis inhibitor,,,,367.814,0.6213,5,3,4,112.73,3,34.21,0.11,0.6065,0.3978,74.81,,,,0,-61.65771631,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.111376517,0,0,Inactive,Inactive,0,12.47723604,,,,,,0,-9.329917606,,,,,,,23.50%,0.6-0.9 hour,90%,None,Hypersensitivity,Category B1,Use with caution
Methazolamide,Antiglaucoma,Proximal tubule bicarbonate reclamation,"CA1, CA12, CA14, CA2, CA4, CA7",carbonic anhydrase inhibitor,,14,7.85,236.278,-1.4238,6,1,1,107.41,0,-0.52,0.21,0.3518,,-19.29,,,,0,-8.083392963,0,0,Inactive,0,-3.382568287,0,0,Inactive,Inactive,0,-39.94196852,0,0,Inactive,0,-20.16486471,0,0,Inactive,Inactive,0,2.272045862,,,,,,0,-19.55469442,,,,,,,55%,14 hours,,None,"Hypokalemia, hyponatremia, hyperchloremic acidosis, cirrhosis, severe liver or renal impairment, adrenal gland failure",NA,Not recommended
Natamycin,"Antifungal, Antibacterial",NA,,fungal ergosterol inhibitor,,,,665.733,0.1197,13,7,3,230.99,14,3.99,-0.01,,,8.099,,,,0,-123.8862319,0,0,Inactive,0,-6.075239446,0,0,Inactive,Inactive,0,-62.80907352,0,0,Inactive,0,0.885313656,0,0,Inactive,Inactive,0,6.409062441,,,,,,0,-28.42120246,,,,,,,,,,NA,Hypersensitivity,Category C,No sufficient information is available
Aztreonam,Antibacterial,Peptidoglycan biosynthesis,,bacterial cell wall synthesis inhibitor,,,5.74,435.44,-1.1725,10,4,7,201.58,2,1.89,-0.06,0.1281,0.135,7.203,,,,0,-17.82056617,0,0,Inactive,0,3.745151877,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.06556952,0,0,Inactive,Inactive,0,2.365865255,,,,,,0,-21.80105294,,,,,,,"Serum protein binding averaged 56% and is independent of dose. Impaired renal function, 36 to 43%.",1.50 hours,1%,None,Hypersensitivity,Category B1,Use with caution
Nizatidine,Anti-ulcerative,"Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion",HRH2,histamine receptor antagonist,,,6.92,331.467,1.3225,8,2,10,83.33,0,-3.09,0.04,,,14.96,,,,0,-59.26556635,0,0,Inactive,0,0.587233609,0,0,Inactive,Inactive,0,-35.70183056,0,0,Inactive,0,2.352303281,0,0,Inactive,Inactive,0,-3.407845034,,,,,,0,-20.24463109,,,,,,,35%,1.50 hours,70%,None,"Hypersensitivity
Addison disease",Category B3,Not recommended
Mebendazole,Anthelmintic,NA,"TUBA1A, TUBB, TUBB4B",tubulin polymerization inhibitor,,,,295.298,2.9722,4,2,3,84.08,0,13.81,0.67,0.1013,0.2334,31.63,,,,1.412537545,-289.1873085,6.3096,35.2826,Inconclusive,11.22018454,-25.78230826,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-11.8704389,0,0,Inactive,Inactive,0,-14.3223736,,,,,,0.630957345,-102.4539625,,,,,,,90-95%,1.10 hours,22%,None,Hypersensitivity,Category B3,Recommended
Nitrofurantoin,Antibacterial,NA,,DNA inhibitor,,,,238.159,0.0735,6,1,3,118.05,0,21.5,-0.2,0.01764,0.1622,14.81,,,,39.81071706,-75.70760384,0,0,Inactive,39.81071706,-12.15534096,0,0,Inactive,Inactive,39.81071706,-27.0930021,39.8107,97.9678,Inconclusive,39.81071706,-12.23198221,39.8107,41.9543,Inconclusive,Cytotoxic,0,-0.499793327,,,,,,0,-18.3806785,,,,,,,90%,0.97 hours,87%,None,"Renal failure (anuria, oliguria, or CrCl <60 mL/min)
Pregnancy at term (38-42 weeks of gestation)
History of hepatic dysfunction/cholestatic jaundice with nitrofurantoin
Neonates (<28 days)
Hypersensitivity",Category A,Use with caution
Repaglinide,Antidiabetic,"ABC transporters, Insulin secretion","ABCC8, KCNJ11, PPARG",insulin secretagogue,,106,6.97,452.595,5.2199,4,2,10,78.87,1,0.78,0.08,0.4307,0.06595,7.8,,,,0,-21.37024321,0,0,Inactive,0,0.785861679,0,0,Inactive,Inactive,0,7.507815586,0,0,Inactive,0,4.746004284,0,0,Inactive,Inactive,0,19.26168264,,,,,,0,-43.60381092,,,,,,,>98%,0.87 hours,56%,gemfibrozil,"Hypersensitivity
Diabetic ketoacidosis",Category C,Not recommended
Flunisolide,Anti-inflammatory,Neuroactive ligand-receptor interaction,NR3C1,cytochrome P450 inhibitor,,,9.1,434.504,2.2747,6,2,2,93.06,9,-4.09,-0.07,0.0848,0.1937,12.51,,,,0,-8.569648006,0,0,Inactive,0,-2.746354367,0,0,Inactive,Inactive,0,0.874872549,0,0,Inactive,0,-0.359080262,0,0,Inactive,Inactive,0,-8.057623359,,,,,,0,-9.463560912,,,,,,,Approximately 40% after oral inhalation,1.68 hours,6.70%,NA,NA,Category B3,Use with caution
Isosorbide dinitrate,Vasodilator (coronary),NA,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1",nitric oxide stimulant,,,,236.136,-1.0622,8,0,4,123.2,4,-9.77,0.11,0.07718,,33,,,,0,-141.3792057,0,0,Inactive,0,-9.50521202,0,0,Inactive,Inactive,0,1.320993622,0,0,Inactive,0,4.192086162,0,0,Inactive,Inactive,0,-1.774414316,,,,,,0,-25.48447319,,,,,,,very low,1.70 hours,22%,"avanafil
riociguat
sildenafil
tadalafil
vardenafil","Hypersensitivity; Severe anemia, shock, markedly low blood pressure",Category B1,Use with caution
Cimetidine,Anti-ulcerative,"Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion","HRH2, SLC29A4, SLC47A1, SLC47A2",histamine receptor antagonist,,500,6.3,252.347,0.5974,4,3,5,88.89,0,-12.58,-0.07,0.01447,0.04968,17.13,,,,0,-52.87610281,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.07875058,0,0,Inactive,Inactive,0,-1.200371473,,,,,,0,-3.749997116,,,,,,,15-20%,2.20 hours,60%,Dofetilide; eliglustat; lomitapide; pimozide,Hypersensitivity,Category B1,Not recommended
Furazolidone,"Antibacterial, Antiprotozoal",NA,,bacterial DNA inhibitor,,,,225.16,0.9739,6,0,3,98.18,0,41.74,-0.01,,0.1034,19.33,,,,0,-37.64639583,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-3.270192183,0,0,Inactive,Inactive,0,-12.59640374,,,,,,0,-33.75129087,,,,,,,,10 minutes,,NA,NA,NA,NA
Belumosudil,Autoimmune disease treatment,Chemokine signaling pathway,ROCK2,Rho-associated kinase inhibitor,,,,452.518,4.8201,6,3,7,104.82,0,-8.64,1.65,,,-34.99,,,,0,-115.9486971,,,,12.58925412,-69.41061446,,,,,,,,,,,,,,,,0,-4.624684727,,,,,,0,-24.79763519,,,,,,,,,,NA,NA,,Not recommended
Tepotinib (EMD 1214063),Antineoplastic,"Ras signaling pathway, PI3K-Akt signaling pathway, ",MET,tyrosine kinase inhibitor,,,,492.583,4.00788,8,0,7,96.93,0,,,,,,,,,39.81071706,-9.879535887,,,,0,-99.1826676,,,,,,,,,,,,,,,,12.58925412,76.02991964,10,72.8017,Inconclusive,,,0,-15.09034285,12.5893,89.2776,Inconclusive,Cytotoxic,,,,,,NA,NA,,Not recommended
Telotristat,Antidiarrheal,"Tryptophan metabolism, Serotonergic synapse

",TPH,Tryptophan hydroxylase inhibitor,,,,546.937,4.51012,8,3,8,142.17,2,,,,-0.05214,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0.69380889,,,,,,0,1.602287202,,,,,,,,,,"doravirine
lonafarnib",NA,Category B3,Not recommended
Fexinidazole,Antiparasitic,,,,,,,279.321,2.6292,6,0,5,70.19,0,19.95,0.02,,0.1901,14.15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lonafarnib,"Hypersensitivity
Hepatic impairment",NA,NA
Umbralisib,Antineoplastic,"Inositol phosphate metabolism, Chemokine signaling pathway, FoxO signaling pathway, Phosphatidylinositol signaling system, PI3K-Akt signaling pathway, Wnt signaling pathway, Hedgehog signaling pathway, B cell receptor signaling pathway
","PIK3CD, CSNK1E ",,,,,571.559,6.6627,8,1,6,109.06,1,24.32,-0.05,,,19.1,,,,0,2.26298998,,,,0,-0.889729839,,,,,,,,,,,,,,,,0,10.98489712,,,,,,0,-8.664528874,,,,,,,,,,NA,NA,NA,NA
ZILEUTON,Antiasthmatic,Arachidonic acid metabolism,ALOX5 ,Arachidonate 5-lipoxygenase inhibitor,,,,236.296,2.7322,3,2,2,66.56,1,,0.03,-0.00439,0.2291,9.14,,,,6.309573445,-18.63245659,6.3096,38.1681,Inconclusive,0,15.53924379,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-1.35771927,,,,,,0,-26.24428017,,,,,,,,2.5 hours,,flibanserin,"Hypersensitivity
Liver disease",NA,Not recommended
Dydrogesterone,Menstruation disorder agent,"Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway


",NR3C3 (PGR),Progesterone receptor agonist,,,6.9,312.453,4.4995,2,0,1,34.14,6,,0.63,0.5447,0.01426,17,,,,0.707945784,-50.03005857,0.7079,34.9741,Inconclusive,0,-3.848148201,0,0,Inactive,Inactive,39.81071706,-24.5126191,39.8107,84.0755,Inconclusive,0,3.135703538,0,0,Inactive,Inactive,0,-1.381872808,,,,,,0,-6.752608153,,,,,,,,"Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours",28%,NA,NA,Category B3,Not recommended